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 ABSTRACT 
 
Urinary incontinence (UI) is a common, debilitating condition investigated by 
urodynamics (UDS). UDS is invasive and not 100% accurate and thus less invasive 
methods such as the electronic Personal Assessment Questionnaire (ePAQ) require 
further investigation. This thesis involved a systematic review assessing 11 studies 
reporting on the clinical uses of ePAQ and demonstrated its reliability in assessing 
quality of life (QoL) but there were no studies found which had assessed predictive 
ability. The quality and accuracy of UDS traces performed as part of a large 
diagnostic accuracy study were assessed and recommendations made for 
improvement in the quality performance. Finally a prospective, consecutive study 
involving 390 women assessed the ability of ePAQ to predict a diagnosis of DO on 
UDS in women with overactive bladder (OAB) and of urodynamic stress incontinence 
(USI) on UDS in women who have stress urinary incontinence (SUI) and 
demonstrated fair predictive ability. There was a positive relationship between OAB 
and SUI scores and a positive UDS diagnosis.  Further research is required to 
assess whether ePAQ can be used in a predictive model with other predictors e.g. 
symptoms and examination findings to better predict disease and treatment 
outcomes. 
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CHAPTER 1: INTRODUCTION 
  
Background 
Urinary incontinence is a condition that can adversely affect the physical, 
psychological and social well-being of the affected individual, as well their friends and 
family1.  This can have a substantial impairment on quality of life (QoL), particularly in 
regards to emotional symptoms, general well-being and sexual health 2, 3. 
 
The International Continence Society (ICS) define urinary incontinence (UI) as “the 
complaint of any involuntary leakage of urine” 4. UI is a common symptom that can 
affect both sexes; although, women are more commonly affected. This can occur in 
women of all ages, with many factors potentially predisposing UI (see Table 1). 
Often self-esteem is lowered and due to the fear/embarrassment of this condition and 
seeking treatment, the emotional and health related quality of life (HRQOL) may 
become more of an issue to the sufferer 5. There are also significant financial 
implications, which include the costs of pads, prescription costs and time off work 6, 7.  
 
It is important to try and establish the cause of UI in order to initiate treatments and 
care pathways for the affected individual. However, UI may occur due to a number of 
abnormalities of the lower urinary tract (LUT) and/or illnesses, thus the aetiology in 
most cases is unknown, resulting in difficulties with the management of the condition. 
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 Table 1: Potential risk factors for urinary incontinence 
Diabetes insipidus Excessive drinking 
Diabetes mellitus High caffeine and alcohol intake 
Obesity (Body Mass Index >30) Age 
Previous pelvic surgery Post-menopausal urogenital atrophy; 
urinary infections 
Pelvic mass (e.g. fibroids) Psychological issues  
Pregnancy and vaginal delivery Neurological disease 
Parity Complex medical history- combined 
conditions e.g. congestive cardiac failure, 
endocrine and renal impairment 
Drugs (e.g. diuretics, cardiac drugs) Toilet habit (e.g. prolonged voiding times) 
 
Lower Urinary Tract  
The lower urinary tract comprises of the bladder and urethra, which serves as a 
functional unit in the storage and voiding phase of the micturition cycle. The pelvic 
floor supports these two structures. Lower urinary tract symptoms (LUTS) are divided 
into three groups; storage, voiding and post micturition symptoms, these symptoms 
can vary in severity 8.  Table 2 shows an adaptation of the groups of LUTS that also 
incorporates OAB and sensory symptoms. 
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Table 2: Symptoms of the Lower Urinary Tract  
Storage Voiding Post micturition Sensory 
Frequency  Poor flow Needing to revisit 
the toilet soon after 
voiding 
Increased bladder 
sensation (earlier 
desire to void), 
Urgency Hesitancy Post voiding dribble reduced bladder 
sensation- desire to 
void occurs later 
than previously 
experienced 
Nocturia Intermittent flow Feeling of 
incomplete 
emptying of 
bladder 
Bladder pain 
Urgency urinary 
incontinence 
Straining - dysuria 
- Terminal dribble - - 
 
Bladder Anatomy and Physiology 
The urinary bladder is a flexible organ composed of three layers: transitional 
epithelium, a layer of smooth muscle (the detrusor muscle) and an adventitial layer of 
connective tissue on the outside. Neurological control of micturition or urination 
involves the central nervous system (CNS). This determines whether the bladder is 
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used to store or expel urine. Normally the bladder will fill over a period of 2-4 hours, 
as it fills the individual becomes increasingly aware of the need to pass urine. 
Changes at any level of this complex hierarchy can cause bladder dysfunction, 
resulting in symptoms. Neurological, anatomical and psychological changes can 
affect the processes that are involved in controlling micturition 9 . 
 
Overactive Bladder 
Overactive bladder (OAB) is defined as “a symptom complex of urinary urgency (an 
intense, sudden desire to void), with or without incontinence, increased urinary 
frequency or nocturia in the absence of infection or other proven pathology” 10.  
OAB is a storage symptom with an estimated 10-20% of the adult population being 
affected by it; millions of people worldwide have this condition and it increases with 
age11, 12. In a large, population-based epiLUTS study, the prevalence of OAB was 
found to be 12.8% 12, 13. Various demographics were collected during the study and 
they found that LUTS increased with age and were highly prevalent amongst men 
and women aged >40years. With an increasing ageing population and advances in 
healthcare, the burden of OAB is likely to increase over the next few decades. 
Affected women tend to implement ‘coping mechanisms’ in order to reduce the 
impact of their symptoms upon their daily living. Fluid restriction, avoiding going too 
far away from a toilet and emptying the bladder ‘just in case’ (before leaving home) 
are examples of coping mechanisms 14. People typically seek help 6-12 months after 
their first onset of symptoms 15. The true scope of this problem may be unknown due 
to under-reporting arising from the social embarrassment that is associated with this 
problem 16. It has been reported that urgency urinary incontinence (UUI) is more 
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bothersome than stress urinary incontinence (SUI) (involuntary leakage of urine 
caused by physical exertion). This is recognised as a predictive factor for depression 
and anxiety 17. Mixed urinary incontinence (MUI) is defined as a “complaint of 
involuntary loss of urine associated with urgency and also effort or physical exertion 
or on sneezing or coughing” 10.  Although the term MUI incorporates mixed 
symptoms, it does not inform the clinician as to which symptom is the most 
bothersome to the patient. 
 
Pathology of overactive bladder 
There are a number of risk factors that can potentially contribute to the worsening of 
OAB symptoms, including urinary tract infection, calculi, inflammation, obstruction 
and oestrogen deficiency 18. 
There are four main hypotheses that attempt to explain the pathophysiological basis 
for OAB. These are the neurogenic, myogenic, afferent hypotheses, and the 
peripheral autonomy (integrative) theory.  
 
Neurogenic theory 
Changes in the central nervous system pathways, leading to an imbalance that 
increases bladder excitation. Inhibition is reduced and there is an increased afferent 
input19. 
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Myogenic theory 
Partial denervation of the detrusor causes an alteration in the properties of the 
smooth muscle. This may lead to an increase in spontaneous excitability and 
resulting in untimely bladder contractions, leading to urgency 20. 
 
Afferent Theory 
Afferent mechanisms have been highlighted as potential factors involved in the 
sensory basis of the OAB diagnosis 19. C-fibres are generally quiescent during 
normal voiding, but they may be critical for symptom generation in pathologic 
conditions (Sun and Chung, 2009) 21. For example, changes in the CNS pathways, 
denervation of the detrusor muscle and alterations in functional cells in the bladder 
wall may lead to OAB.   
It has been concluded by several authors that the c-fibres form a new afferent 
pathway and establish the mechanism of bladder pain and detrusor overactivity22, 23. 
 
Peripheral (Integrative) theory 
Drake et al (2001) 21  proposed that the bladder is modular;  an increased bladder 
sensation can occur  due to exaggerated localised modular contraction. Detrusor 
overactivity is caused by an enhanced modular activity like alterations in the normal 
properties, or interactions of various functional cells in the bladder wall 24. 
 
Current practice in management of Urinary Incontinence 
The initial clinical assessment of any woman who is being investigated for UI should 
include her UI being categorised. The National Institute for Health Care Excellence 
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(NICE) clinical guidelines on urinary incontinence (CG 171, 2013) state that the 
woman’s UI should be categorised as stress urinary incontinence (SUI), mixed 
urinary incontinence (MUI) or urgency urinary incontinence (UUI) and overactive 
bladder (OAB) to prioritise the treatment of the predominant symptom.  
 
Clinical History  
A thorough consultation (clinical history) will help to establish the type of UI 
experienced and its effects on the individual. History taking should be focused on the 
main symptoms of OAB: nocturia, urgency, frequency and urgency incontinence 15. 
Information should be collected on the duration, type and severity of symptoms as 
well as the impact these symptoms have on quality of life (QoL). Further information 
should be obtained about any co-existing medical, surgical and /or gynaecological 
conditions and also factors such as diet, oral fluid intake and medications.  
 
Bladder diaries 
These are useful tools in the investigation of LUTS and also to assess treatment 
response 25.  Completion of bladder diaries allows evaluation of fluid intake, fluid 
output and volumes voided as well as number of incontinence episodes (day and 
night), twenty-four hour urine production and provoking factors such as activities 
(skipping, jogging, coughing) 25 .  
 
Physical examination 
A vaginal examination is carried out if a woman complains of a “bulge” or “something 
coming down through the vagina”. This is to rule out pelvic organ prolapse (POP) and 
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vaginal atrophy. Treatment options can then be explored for women with 
symptomatic POP (NICE CG171, 2013). 
 
Investigations 
Whilst OAB is a symptomatic or clinical diagnosis, an assessment that excludes any 
underlying cause for LUT dysfunction like urinalysis for urinary tract infection should 
be performed.  
A urine dipstick test should be undertaken in all women who present with UI at their 
first clinical consultation.  As there are other factors that may contribute to their 
symptoms (Table 1), the presence of blood, glucose, leucocytes and nitrates as well 
as protein should be detected.  
 
The NICE guidance  on urinary incontinence (CG171, 2003) state that if a woman 
has symptoms of a UTI and their urine tests positive for leucocytes and nitrates, a 
midstream urine specimen should be taken women for culture and sensitivity of 
antibiotics. They should then be prescribed a course of antibiotics (pending culture 
results).  
 
Questionnaires are increasingly used in health care in order to measure health-
related QoL on an objective scale. These are either generic or specific to a particular 
condition. Generic questionnaires measure general concepts such as general coping 
strategies whilst the condition-specific questionnaires measure the differences 
between individuals with the same condition. However, the generic scoring systems 
are insensitive when dealing with a specific condition such as OAB 15.  
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Therefore, there may be a poor correlation in the differences between the patients 
and the grading of responses to treatment. Indeed, disease specific questionnaires 
are more appropriate in urogynaecology and in other clinical areas (such as clinics 
for women suffering with heavy menstrual bleeding). In order for a questionnaire to 
be considered a good, validated tool, adequate psychometric qualities must be 
demonstrated 26. NICE have a number of recommended symptom scoring and quality 
of life questionnaires; which are incontinence-specific when therapies are being 
evaluated (Appendix 1). 
 
Urodynamics 
Urodynamics (UDS) is a diagnostic assessment of the lower urinary tract. It 
comprises of a series of interactive tests that look at the function of the bladder and 
urethra during both the filling and voiding phase with the aims of reproducing the 
patient’s symptoms and secondly to provide a pathophysiological explanation for the 
patient’s symptoms 27.  
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Figure 1: Urodynamics trace (left) and video urodynamics (right)  
 
UDS consists of uroflowmetry, filling cystometry and pressure flow or voiding 
(cystometry) 28. Uroflowmetry measures the flow rate during the voiding stage, the 
test involves the patient passing urine into a special toilet that measures urine flow 
rate  Multichannel cystometry evaluates the pressure and volume relationship in the 
bladder at both the filling and voiding stages. The detrusor pressure is calculated by 
subtracting the abdominal pressure (obtained from the catheter transducer inserted 
into either the rectum or vagina) from the intravesical pressure measured by bladder 
line. During filling cystometry, the patient is asked to report any symptoms 
experienced like first desire, normal desire, strong desire to void, pain, urgency, 
incontinence etc. At the end of the test, the filling catheter is removed, and whilst the 
bladder and rectal catheter remain in situ, various provocation manoeuvres such as 
jumping, coughing, and running water are carried out. The objective is to try and 
identify provoked detrusor overactivity (DO) or urodynamic stress incontinence (USI). 
The patient is then instructed to void with the transducers in situ; this is to record 
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opening and maximum detrusor pressures, as well as the voiding pattern. This 
process is known as the voiding cystometry phase of urodynamics (UDS).  
In a bladder that is normally compliant, large volumes of urine can be accommodated 
without any significant rise in the detrusor pressure, however if the elasticity of the 
bladder is reduced and the pressure rises whilst being filled, the bladder is deemed 
to have low compliance.  
 
Urinary symptoms can arise due to neurological disease in the brain, the suprasacral 
spinal cord, the sacral spinal cord or the peripheral nervous system. Damage within 
each of these areas tends to produce characteristic patterns of bladder and sphincter 
dysfunction (NICE CG148, 2012) 29.  
 
Medical conditions including Parkinson’s disease, stroke, multiple sclerosis, spinal 
cord injuries and tumours of the central nervous system can cause a neurogenic 
bladder. Neurogenic detrusor overactivity (DO) can occur when there is evidence of 
DO in a patient has a neurological disorder. 
 
Urodynamics (UDS) is ideally performed in the sitting or standing position 28, 30. The 
aim of the test is to reproduce patient’s symptoms. Multiple diagnoses can be given 
following UDS tests: detrusor overactivity (DO), urodynamic stress incontinence 
(USI), a combination of DO and USI, voiding dysfunction (VD) and a ‘stable/normal’ 
bladder. 
 DO - defined as the occurrence of involuntary detrusor contractions during 
filling cystometry. These contractions may occur spontaneously or as a result 
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of provocation, they produce a wave form on the cystometrogram and vary in 
amplitude and duration 10. 
 USI - is defined by the ICS/IUGA (2010) as the finding of involuntary leakage 
during cystometry; this is associated with increased intra-abdominal pressure, 
in the absence of a detrusor contraction. 
 
UDS is often described as the ‘gold standard’ for evaluating LUTS 31. However, some 
studies have shown that UDS can be inaccurate and does not always correlate to the 
patient’s symptoms 32-34. For instance, a proportion of women who have OAB 
symptoms do not have a clinical diagnosis of DO following UDS. One reason for this 
may be because UDS does not mimic the ‘normal physiology’ of the bladder.  
Although UDS may not be necessary for the routine management of all patients, 
objective data are provided from the procedure, which may guide medical and 
surgical treatment 35. 
UDS is a costly procedure at approximately £212 per person and is also an invasive 
diagnostic test that has an associated risk of urinary tract infections 36. 
UDS is indicated prior to implementing surgical treatments, following failure of 
conservative management and medical treatments. NICE (CG171, 2012) 
recommends invasive treatments like Botulinum toxin A or neuromodulation in 
patients who have failed conservative therapies and have Detrusor Overactivity (DO). 
 
Ambulatory UDS is an extended version of the laboratory UDS, whereby this is often 
performed over a four-hour period. This test may be offered if the patient symptoms 
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have not been reproduced by the standard UDS. This test may be more sensitive in 
detecting the rate of DO than the conventional UDS 37. 
 
The advantages of ambulatory UDS are that the patient is given a lot more time to 
present and report their symptoms. The situation where the patient may usually leak 
is often without the presence of any clinicians. A diary is kept throughout the duration 
of the test and specific buttons are pressed on the machine to indicate the symptoms 
experienced, i.e. leaking, walking or experiencing urgency. 
 
Options for treatment 
Behavioural modification can be implemented whilst using bladder diaries and factors 
such as caffeine reduction and bladder retraining should also be initiated  38, 39. 
Currently, physiotherapy treatment options for UUI include pelvic floor muscle training 
(PFMT) or pelvic floor exercises. This treatment is the most common used for women 
with SUI, although it is sometimes used for women who present with MUI or UUI.  
A trial of supervised PFMT (at least 3 months duration) should be offered to women 
with SUI (NICE CG171, 2012). 
It is known that the detrusor muscle contraction can be inhibited by a pelvic floor 
contraction, induced by electrical stimulation 40.  Inhibition involves an automatic 
increase in tone for the pelvic floor muscle and urethral striated muscle; therefore, 
voluntary pelvic floor contractions may provide some benefit to those who have UUI 
(by controlling these symptoms) 41.  
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Whilst conservative measures are desired as first line treatment, an integral part of 
OAB management includes drug therapy for most symptomatic women. 
Antimuscarinic/anticholinergic medication is the mainstay of treatment; however, side 
effects associated with these result in difficulties with compliance. The NICE 
guidelines (CG171) advise that following the failure of conservative treatment, a trial 
of anticholinergics should be offered. 
An anticholinergic is a substance that blocks the neurotransmitter acetylcholine in the 
central and peripheral nervous system. Anticholinergic drugs inhibit the 
parasympathetic nerve impulses; they selectively block the binding of the 
neurotransmitter acetylcholine to its receptor in the nerve cells. The rationale for 
using anticholinergic drugs in the treatment of overactive bladder syndrome is to 
block the parasympathetic acetylcholine pathway and thus abolish or reduce the 
intensity of detrusor muscle contraction.42  
Electronic personal assessment questionnaire (ePAQ) is one such questionnaire 
which is being used in a lot of urogynaecology departments throughout the country to 
assess the pelvic floor specific QoL (detailed in chapter 2). We wanted to study the 
evidence on diagnostic, prognostic and other utilities of ePAQ. We also wanted to 
assess whether this instrument could be used to reduce the need for invasive tests 
like urodynamics. 
 
 
 
 
 
15 
 
ELECTRONIC PERSONAL ASSESSMENT QUESTIONNAIRE (ePAQ)  
The electronic Personal Assessment Questionnaire-Pelvic Floor (ePAQ-PF) was 
developed by the Sheffield Teaching Hospitals NHS Trust in 2002. The concept 
behind the development of this questionnaire was due to the perceived need to 
reduce the use of paper questionnaires and use computer interviewing 40. It was 
thought that this would improve communication and patient assessment, particularly 
in regard to the sensitive issue of pelvic floor disorders.  
In this thesis, unless otherwise stated; ‘ePAQ’ should be understood to mean ePAQ-
PF.  
 
The ePAQ has undergone rigorous psychometric testing and test-retest reliability and 
is known as a validated and robust tool for measuring QoL in relation to pelvic floor 
dysfunction 40. The completion of paper questionnaires can become a burden to the 
patient and might be onerous to collate for a clinician 43. In contrast, computerised 
questionnaires have been known to achieve higher response rates in terms of 
completion and participants have also found these easier to complete 44.   
 
There are 132 items in this questionnaire to provide a detailed assessment into pelvic 
floor symptoms and health-related QoL45. The ePAQ is a self-administered, 
interactive, computer-based questionnaire that comprises of four dimensions; 
measuring urinary, bowel, vaginal and sexual symptoms, looking at their related 
impact and effect on QoL. In the four dimensions there are either four or five scored 
domains, each one comprising three to seven items. A scoring algorithm is used and 
each item has a scoring system between 0 and 3 (0 indicates best and 3 worst health 
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status).  A scale of 0-100 is produced at the end of the questionnaire indicating the 
best health (0) and the worst health status (100). Each page of the ePAQ will include 
a question about how often the symptoms occur and its effect on the individual’s 
QoL. The results from the questionnaire do not show the answers to any of the 
questions. Following completion, a report is generated and symptoms scores are 
categorised by the specific groups of the pelvic floor function. 
 
Currently, ePAQ is used to improve clinical consultation and assess treatment/ QoL 
outcomes in patients who complain of pelvic floor symptoms. Figure 2 shows an 
example of the report produced after a completed questionnaire. 
The last two items in the questionnaire seek consent for use of patient data. In 
relation to service evaluation, the first asks: “Are you willing to allow confidential use 
of your answers in order to evaluate the care you receive?” (Yes/No). The second 
relates to evaluation of the questionnaire and asks: “Are you willing to allow 
confidential use of your answers to check how this questionnaire is working? 
(Yes/No).  
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Figure 2 Picture of a completed ePAQ 
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Potential uses of ePAQ as a predictive tool in LUTS 
The bladder has been described as an unreliable witness 46. UDS is considered to be 
the gold standard diagnostic test for investigating lower urinary tract symptoms 
(LUTS). The UDS can discriminate between a person with the disease (i.e. DO or 
USI) and a person without the disease (i.e. stable bladder) to give the post-test 
probability of a disease. However, it is invasive, expensive and can give a risk of 
urinary tract infection (UTI). Rosier (2013) states that the invasiveness of UDS 
remains a drawback; raising the threshold for its use 47. There is widely available 
evidence on the clinical relevance of UDS, however, it is somewhat fragmented 
(Rosier, 2013). There are variations within clinical practice, the need for continuous 
quality control and also the correlation between patient symptoms and the results of 
the UDS investigation. Schafer et al (2002) 27 identify that there are limitations with 
the UDS equipment and also the lack of a consensus in relation to the right method 
of measurement including, the signal processing, documentation and interpretation. 
The clinical utility of any diagnostic tool can be judged by whether the test is 
reproducible, can confirm the diagnosis and if the clinical outcome of treatment is 
better than having used the tool30. With UDS being invasive and time consuming, 
alternative methods have been sought out in order to diagnose detrusor 
overactivity48.  
 
Until and unless there is another method that proves to be more reliable, the UDS will 
remain the gold standard investigation. There is thus a need to consider other less 
invasive tools that may allow us as clinicians to identify a sub-group of women with 
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LUTS that are more likely to have pathology (i.e. either DO or USI) and thus most 
benefit from the invasive test i.e. UDS. 
 
The ePAQ is a non-invasive, reliable and relatively easy to use tool 40, 53, 54 and we 
hypothesize, its urinary domain may have sufficient predictive value to reduce the 
need for invasive UDS. To date, there have been no data on the diagnostic value of 
ePAQ in accurately predicting the urodynamic diagnoses of women who have OAB 
symptoms. 
 
Aims and objectives 
It is hypothesised that women who have higher scores on ePAQ for OAB or SUI will 
have a higher likelihood of DO or USI respectively diagnosed at the time of UDS. We 
aimed to explore whether ePAQ has good diagnostic accuracy for detrusor 
overactivity and urodynamic stress incontinence which might enable us to reduce the 
need to perform UDS.  
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Objectives: 
This thesis has the following objectives: 
1. To perform a systematic review of the literature to assess the utility of the 
ePAQ-PF in clinical practice for women with lower urinary tract symptoms. 
 
2. To perform quality assurance of the gold standard test of Urodynamics. 
 
3. To assess the ability of the electronic personal assessment questionnaire 
(ePAQ) to predict a urodynamic diagnosis of detrusor overactivity (DO) in 
women with OAB and urodynamic stress incontinence (USI) in women who 
have SUI. 
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CHAPTER 2: SYSTEMATIC REVIEW OF 
ELECTRONIC PERSONAL ASSESSMENT 
QUESTIONNAIRE TO ASSESS CLINICAL UTILITY IN 
WOMEN WITH LOWER URINARY TRACT 
SYMPTOMS 
 
Introduction 
The ePAQ system provides a validated approach to the assessment of pelvic floor 
symptoms. It is used to assess responsiveness to therapies and assess quality of life 
in women. It provides a detailed software analysis from a set of user-friendly 
questions. When patient responds with assent to an item about a particular symptom, 
an impact question relating to the ‘bothersomeness’ of that symptom is automatically 
presented. These questions relating to ‘bother’ are only displayed if the patient states 
they have an issue with that symptom. The patient’s most bothersome symptoms are 
highlighted and presented as a graph and also numerically (Figure 2). The overview 
of their ePAQ report can then be used to aid the clinical consultation, by questioning 
the patient on her symptoms identified on her report.  
 
Systematic reviews are considered a key element of evidence-based healthcare 49. 
We wanted establish the evidence base for using ePAQ in clinical practice. In 
particular, we wished to assess whether any previous research had been performed 
to assess its predictive ability for UDS diagnoses. A scoping search conducted in 
22 
 
2013 did not find any evidence on diagnostic accuracy of ePAQ and UDS diagnoses 
and thus this systematic review was then extended to assess the literature on all 
clinical utilities of the ePAQ.  
 
Methods 
Four part question 
Population: women with pelvic floor symptoms 
Intervention: electronic pelvic floor assessment questionnaire 
Comparison: none 
Outcomes: effectiveness, diagnosis, prognosis, qualitative data 
Study design: prospective or retrospective cohort studies, case series 
 
Literature Search 
The following databases were used: The Cumulative Index to Nursing and Allied 
Health (CINAHL), Cochrane database, Medical Literature Analysis and Retrieval 
System Online (MEDLINE), Excerpta Medica Database (EMBASE), National Library 
for Health, Meta Register of controlled trials and Google Scholar (from ePAQ 
inception 2004-October 2013). Various relevant key words, word variations and 
Medical Subject Headings (MeSH) were used without language restrictions. The key 
words used in the search were: ePAQ, electronic Personal Assessment 
Questionnaire, electronic Pelvic Floor Assessment Questionnaire, quality of life 
questionnaire, overactive bladder, urinary incontinence and prolapse. In order to 
explore any relevant literature that related to the research question a combination of 
Boolean operators ‘OR’ and ‘AND’ were utilised to bring the key words and topics 
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together. The CINAHL, Cochrane and EMBASE databases provided a number of 
results in relation to questionnaires (Appendix 2). 
 
Study selection and data extraction 
Two review authors (PM- Consultant in Urogynaecology and SM- a urogynaecology 
research nurse) scrutinised the electronic searches consisting of studies where 
ePAQ had been used as a form of measuring QoL and selected potentially relevant 
manuscripts on the basis of the title and abstract. Full manuscripts of the potentially 
relevant studies were obtained. A final decision on inclusion or exclusion of the 
manuscripts was made following review of the full manuscripts (Figure 3). Included 
studies had to fulfil the criteria as described in the clinical question above. A list of 
excluded manuscripts and the rationale for exclusion can be found in Appendix 3. 
The required information from the primary studies was extracted and details about 
the participants, study, and outcomes were noted. 
 
The selected studies were then assessed for methodological quality using the 
Newcastle Ottawa Scale 50. This scale was chosen as it has undergone reliability and 
validity assessment. One of its strengths is that it is a convenient and fairly simple 
tool to use for the quality assessment of non-randomised studies. Our clinical 
question considered a study design which consisted of a selection of cohort studies. 
The Newcastle Ottawa Scale has a star rating system used to indicate the quality of 
a study. Quality was defined as the confidence that the study design, conduct and 
analysis minimised bias in the estimation of test accuracy. The risk of bias was 
regarded as low if a study obtained four stars for selection, three stars for 
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ascertainment of exposure and two stars for comparability 50. A medium risk of bias 
was regarded as studies with two or more stars for selection, one for comparability 
and two for exposure. Any study that scored one or zero stars for selection, exposure 
or comparability was considered to have a high risk of bias. Following the initial 
literature search, relevant articles (which fulfilled the 4 part clinical question) were 
selected. We looked at the rationale for each study, the methods and materials used 
to obtain the data and the results of each study. We then grouped the similar themes 
from each study and tabulated them in accordance to the following:  predicting 
prognosis, treatment response, test-retest reliability and qualitative purposes.  
 
Results 
A total of 15 publications were identified in the electronic search and 11 studies were 
included in this review (Figure 3). 
The studies included in the systematic review were tabulated into various categories: 
predicting prognosis, treatment response, test-retest reliability and 
qualitative/miscellaneous studies (see Tables 3a-3d). The methodology, findings and 
the strengths/limitations have been listed. 
The qualitative studies included semi-structured interviews and cross-sectional 
surveys being conducted on women who were seen in a urogynaecology unit and 
had completed an ePAQ. Prospective cohort studies using ePAQ for women who 
had undergone surgery included women who completed the ePAQ pre and 
postoperatively. The majority of the study population were of Caucasian origin and 
the mean age groups varied from 29.7 years to 60.5 years. 
25 
 
The sample population in the various studies ranged from 34 to 4,506 women. The 
studies were conducted for a few months up to three years. 
 
Figure 3: Selection process for studies included in the electronic Personal 
Assessment Questionnaire systematic review 
 
Total citations 
identified  from the 
elctronic searches 
on ePAQ: n=15  
Full manuscripts 
retreived for 
detailed evaluation 
and inclusion: n=11 
Sources: from 
electronic searches 
n=8 
Sources: obtained 
directly  from the 
primary author/ 
corresponding 
author on 
manuscript   
n=3 
Citations excluded 
after screening 
title, abstract and 
methods used: n=4 
(used a different 
questionnaire) 
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Table 3a: Details of studies included in the systematic review on electronic Personal Assessment Questionnaire- 
pelvic floor: predicting prognosis. 
Author, Year Title Sample Methodology Findings Strengths/limitations 
Jha et al 
(2009)
51 
Factors 
influencing 
outcome following 
the tension-free 
vaginal tape 
(TVT). 
100 women who 
were undergoing 
TVT and had 
completed ePAQ 
pre-operatively and 
3 months post-
operatively were 
included in this 
study. (January 
2006-May 2007) 
A prospective 
observational study 
which aimed to 
evaluate factors which 
may influence the 
outcome with TVT. 
Linear regression was 
used for analysis. 
 
85% had urodynamic stress 
incontinence (USI). 
Women who had more severe 
symptoms preoperatively had a 
greater improvement in SUI. 
All dimensions on the urinary 
domain of ePAQ had improved 
following a TVT. 
Pre-operative data regarding 
bladder test diagnoses was 
provided, indicating the 
rationale for treatment. 
This is the first study looking 
at the effect of severity of pre-
existing symptoms (stress 
urinary incontinence) 
Additional factors which have 
a potential to influence 
outcome of surgery were not 
included-examples of this 
include previous continence 
surgery and also parity. 
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Elenskaia et 
al (2012)
52
 
Pelvic organ 
support, 
symptoms and 
quality of life 
during pregnancy: 
a prospective 
study. 
>18years old and 
had a singleton 
pregnancy (with no 
complications) The 
aim was to evaluate 
changes in pelvic 
organ support and 
pelvic floor 
symptoms during 
their first 
pregnancy. The 
hypothesis was that 
pregnancy is 
associated with 
worsening changes 
of the pelvic floor 
and its function. 
 
182 Women who 
attended their first visit 
to clinic at 20 weeks. 
 150 (82.4%) women 
attended the 36-week 
visit. Of these, 147 
(80.8%) completed 
ePAQ and 148 
(81.3%) had an 
assessment of their 
pelvic support using 
the POP-Q system.  
The mean age = 29.7 years. 
There were no significant 
changes in POP-Q between the 
two visits. 
There were no changes in 
vaginal symptoms. 
There were increased 
symptoms and bothers 
associated with voiding and 
stress urinary incontinence 
during pregnancy. 
Constipation had improved 
(p=0.02). None of the pelvic 
floor symptoms had an impact 
on QoL. 
 
 
Data was unable to be 
provided from the first 
trimester of pregnancy. 
The electronic format of ePAQ 
was not used for this study. 
This may have influenced the 
disclosure of specific 
information. 
 
  
 
2
8 
Table 3b: Details of studies included in the systematic review on electronic Personal Assessment Questionnaire-
pelvic floor: treatment response. 
Author, Year Title Sample Methodology Findings Strengths/limitations 
Jones et al 
(2009)
53
 
Responsiveness 
of the electronic 
Personal 
Assessment 
Questionnaire-
Pelvic Floor 
(ePAQ-PF). 
54 women having a 
tension-free vaginal 
tape (TVT) for 
stress urinary 
incontinence and 47 
undergoing 
prolapse surgery  
ePAQ was 
completed at 
baseline and  3 
months post-
operatively 
The 
responsiveness of 
the questionnaire 
was evaluated 
using effect sizes, 
standardised 
response means, 
responsiveness 
statistic and 
minimally 
importance 
The mean age of the women in TVT 
group was 49.9years (range 35.8 to 
70.3) and 60.5 years for the prolapse 
group (range 35.1 to 79.2).70.4% of 
women who had a TVT felt “much 
better” post-op. 
61.7% of women with prolapse 
repair felt “much better” post-op 
A comparison of mean scores from 
baseline to follow-up (for the TVT 
group) in all domains showed an 
overall improvement, except for the 
bowel domains (IBS, constipation, 
evacuation and continence). An 
improvement in all domains of ePAQ 
for baseline and follow up (prolapse 
A small sample size, the time 
scale of the study was not 
mentioned- difficult to know 
whether the dataset and 
length of study may have 
influenced the outcome 
measure. 
Health changes identified 
through the completion of this 
questionnaire, pre and post 
intervention. 
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difference. group) showed an improvement in all 
domains, except the bowel domains 
for constipation and evacuation. 
Dua et al 
(2012)a
54
 
 
The effect of 
prolapse repair on 
sexual function in 
women. 
474 women who 
had undergone 
prolapse surgery 
between 2008 - 
2010.  
Prospective study 
on women who 
were undergoing 
prolapse repair 
The ePAQ had 
been completed at 
pre and 3 months’ 
postoperative 
intervals. The sex 
(vaginal and 
dyspareunia) 
474 women underwent prolapse 
surgery.393 had completed ePAQ 
and had given consent for their data 
to be used. 
271 women were sexually active 
prior to surgery and 197 had 
completed a pre and post 
questionnaire. 
Significant improvements had been 
recorded by the women who had 
and anterior repair or anterior repair 
Largest prospective study that 
evaluates sexual function 
outcomes following vaginal 
prolapse surgery. 
The main outcomes measured 
were clearly identified through 
focusing on a specific domain 
of the questionnaire. 
The study highlights how 
effective this questionnaire is 
in assessing change in QoL, 
  
 
3
0 
domains were the 
main focus of this 
study. 
 
and vaginal hysterectomy. 
Women who had a posterior repair 
had some improvement in sexual 
function post-operatively.  
following surgery for vaginal 
symptoms.  
 
 
Dua et al 
(2012)b
50 
The effect of 
posterior 
colphorrhaphy on 
anorectal 
function. 
Prospective, 
observational study 
on 60 Caucasian 
women who were 
undergoing 
posterior 
colporrhaphy 
The effect that this 
type of prolapse 
procedure has on 
bowel symptoms 
was the main 
objective of the 
study (January and 
Women who were 
seen in a tertiary 
referral 
urogynaecology 
centre, completed 
ePAQ at their 
initial assessment 
and 3-6 months 
post-operatively.  
Pre and post-
operatively bowel 
scores were 
compared using 
student t-test. 
The mean age = 58.3 years (+/-11.8 
years) and the mean Body Mass 
Index (BMI) was 28.05 (+/-5.2). 
57% had IBS, 62% reported bowel 
continence problems, 81% had 
evacuatory problems and 47% 
constipation 59/60 women had grade 
2 or more prolapse on POPQ.27% 
had Posterior repair with 
perineorrhapy and 73% had just a 
posterior vaginal repair42% of 
women had improved bowel 
evacuation. 
37% had improvements in 
This is the first study to report 
on the overall bowel-related 
quality of life.  
Women from ethnic minority 
backgrounds were not 
included in this study, result 
findings may have differed. 
Follow up was conducted 
between 3 and 6 months, 
results may have differed over 
a longer period of time. 
This study was observational 
and related to one specific 
centre. 
  
 
3
1 
October 2010) 
 
 continence and 61% had seen an 
improvement with bowel related 
QoL. Bowel evacuation and 
continence improved 3-6 months 
post-operatively. 
Jadav et al 
(2013)
55
 
Does sacral nerve 
stimulation 
improve global 
pelvic function? 
43 patients with 
faecal incontinence 
were included. 
 
Women with 
faecal 
incontinence 
completed ePAQ 
pre and post 
treatment. All 
women had sacral 
neuromodulation 
for faecal 
incontinence. The 
data was 
analysed for a 
period of five 
years.  
The mean age = 56.5 years. 
The median follow up was 6.8 
months. 
All women had urinary symptoms. 
81.4% had vaginal symptoms and 
85.7% had described some sexual 
dysfunction. 
There was a significant improvement 
in faecal incontinence and bowel 
related QoL. 
58.1% reported a global health 
improvement, mainly in the bowel 
domain. 
ePAQ has been used to 
confirm improvement in pelvic 
floor function relating to the 4 
domains on the questionnaire. 
9 patients were lost to follow 
up (no completed post-
treatment ePAQ and despite 
efforts to obtain this data, they 
were excluded). 
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Table 3c: Details of studies included in the systematic review on electronic Personal Assessment Questionnaire- 
pelvic floor: test-retest reliability. 
Author, Year Title Sample Methodology Findings Strengths/limitations 
Radley et al 
(2006)
56
 
 
 
 
 
 
 
 
 
 
 
 
 
Computer 
interviewing: 
concept, 
development and 
psychometric 
testing of an 
ePAQ in primary 
and secondary 
care (June 2003 
and January 
2004). 
 
 
 
432 women 
recruited - 
204 in primary 
care and 228 
in secondary 
care. 
 
Cross-sectional 
study of women 
using ePAQ prior to 
appointment. 
Women untreated in 
primary care 
returned a week later 
to complete ePAQ. 
Psychometric testing 
conducted to assess 
whether this 
questionnaire could 
be used to evaluate 
pelvic floor 
In primary care, the findings show that test-
retest analysis was acceptable (p<0.001) and 
alpha co-efficient >0.7. 
In secondary care, 14 domains with the four 
dimensions (urinary, bowel, vaginal and 
sexual symptoms) were consistent.  14 
domains within the 4 dimensions (urinary, 
bowel, sexual and vaginal symptoms) had 
alpha values of >0.7. 
ePAQ was found to be a user-friendly tool 
which may enhance the questioning of 
women with pelvic floor disorders. 
Questions can be omitted 
which may improve non-
response rates 
The patient’s willingness 
for their data to be used 
for audit is recorded. 
The costs of the 
computer software may 
be an issue amongst 
some NHS units. 
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 symptoms. 
Jones et al 
(2008)
57 
 
 
Electronic pelvic 
floor symptoms 
assessment: 
tests of data 
quality of  
ePAQ-PF. 
599 women 
with pelvic 
floor disorders 
completed 
ePAQ. 
A cross-sectional 
survey conducted in 
a urogynaecology 
unit where ePAQ is 
completed as part of 
routine clinical care 
and prior to clinical 
consultation. 
The mean age of the women at time of 
completing the questionnaire was 52.6 years. 
Of the 599 completed questionnaires, 17 
were excluded due to incomplete data. 
3 (0.5%) women declined to answer urinary, 
bowel or vaginal dimensions and 90 (15.5%) 
women declined to answer the sexual 
dimension. 
70.3% women had some bladder concerns; 
45.9% had expressed bowel problems, 
50.2% of the women had vaginal problems. 
The study was set in a 
secondary care unit. 
Primary care women 
were not included and 
therefore it is not 
possible to state whether 
results may have been 
different. 
This study illustrates that 
ePAQ can be used as a 
tool to detect changes in 
pelvic floor disorders. 
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Table 3d: Details of studies included in the systematic review on electronic Personal Assessment Questionnaire-
pelvic floor: qualitative/miscellaneous research. 
Author, 
Year 
Title Sample Methodology Findings Strengths/limitations 
Jha et al 
(2012)
58 
Incontinence 
during 
intercourse: 
myths 
unravelled. 
480 women who 
attended a 
urogynaecology 
unit during the 
months of January 
2006-July 2010.  
Prospective study of 
women referred with 
urinary incontinence. 
They went on to have 
urodynamics and had 
completed an ePAQ. 
The aim of the study 
was establish the 
extent to which coital 
incontinence occurs, 
its impact on QoL  and 
the correlation 
between the different 
urodynamics diagnosis 
and coital leakage  
The mean age = 48.3 years. 
58% of women had USI 
19% of the women had Detrusor 
Overactivity. 
130 women did not complete the 
sexual dimension of the 
questionnaire. 
60% of women who had urinary 
incontinence also reported leaking 
with intercourse.   
 
 
 
This is the largest study looking 
at sexual symptoms and 
urodynamic diagnoses whilst 
using ePAQ to assess its 
effects on sexual function. 
Demographic data in relation to 
ethnicity, parity, body mass 
index may have provided 
further information on this topic 
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Dua et al 
(2013)a
59
 
 
Understanding 
women’s 
experiences of 
electronic 
interviewing 
during the 
clinical episode 
in 
urogynaecology: 
a qualitative 
study. 
 
Initially 34 women 
were approached 
but due to various 
reasons, 20 women 
who had completed 
ePAQ before and 
after pelvic floor 
intervention were 
included in the 
study. 
 
 
Qualitative study 
conducted through the 
use of semi-structured 
interviews. The study 
was conducted 
between July 2009 
and July 2010. 
A thematic approach 
was used to identify 
themes and 
categories. 
 
All women were Caucasian with a 
mean age of 58 years. 
8 themes were identified relating 
to the women’s views on using 
the questionnaire benefit and the 
burden of completing this 
questionnaire. 
Women felt that their 
understanding into their own 
condition had actually improved 
following the completion of ePAQ; 
Communication with their clinician 
had improved as they felt more 
prepared for consultation.  
ePAQ was found to be generally 
acceptable and easy to use. 
Some women found the 
questionnaire to be a burden due 
to its multiple choice format. 
 
A small sample size was used 
over a 1 year period. 
Only Caucasian women were 
interviewed, further interviews 
from women of ethnic minority 
backgrounds may have altered 
the results. 
The potential to enhance 
understanding and educate 
women about their symptoms 
highlighted in this study. 
Due to technical failure, one of 
the interviews was unable to be 
used as part of the final 
analysis. 
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Dua et al 
(2013)b
62
 
The personal 
impact of pelvic 
floor symptoms 
and their 
relationship to 
age. 
A total of 4,506 
women who 
attended 
urogynaecology 
clinics had 
completed ePAQ-
95% of these 
women (4,311) 
gave consent for 
their data to be 
used. 
. 
Symptom frequency 
and impact scores 
were categorised into 
mild, moderate and 
severe. 
These were then 
compared amongst the 
different age groups 
<35, 36-50, 51-65 and 
>65 years. 
 
 
615 women were <35years 
(14.2%), 1,219 (28.2%) were 
aged between 36 and 50 years, 
1,438 (33.3%) were 51-65 years 
and 1,047 (24.3) were >65 years 
at time if completing ePAQ. The 
mean impact scores for OAB, 
SU), voiding dysfunction and 
bladder pain were lower in older 
women. Severe urinary symptoms 
did not show any difference in the 
impact in different age groups. 
Older women had lower impact 
scores for vaginal and bowel 
dimensions. In the sexual 
dimension of ePAQ, older women 
were less bothered by all sexual 
symptoms.  
This is the first study that has 
reported on individual 
symptoms and its relation to 
age  
A large sample size was 
obtained over a 3 year period. 
Previous surgical history and 
medical conditions were not 
included which may have 
Influenced the result findings. 
Women who are treated for 
pelvic floor symptoms in the 
community were not included. 
Results may differ from women 
in primary and secondary care.  
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 Predicting prognosis 
There is the potential to use ePAQ when counselling women about surgical 
interventions (e.g. for continence or pelvic organ prolapse), outcomes and their 
perception of success (post operatively).  Additional co-morbidities may influence 
how successful (or not) a patient perceives her treatment to be. For example, women 
with LUTS and pelvic floor symptoms may have higher expectations of improvement, 
following surgery. 
 
A tension free vaginal tape (TVT) is a surgical procedure undertaken for the 
treatment of SUI. It involves inserting a synthetic polypropylene sling in the mid-
urethral area to provide a hammock effect, relieving leaking associated with activities 
such as laughing and coughing. The ePAQ is often used pre and postoperatively in 
this sub-group of women and can be used to evaluate the subjective effect of the 
procedure. 
 
Jha et al (2009)51  looked at factors that may influence the outcome with women 
having a TVT.  They found that women with more severe symptoms preoperatively 
had a significantly greater improvement in SUI symptoms (p < 0.001) and QoL (p = 
0.016). Women with more severe SUI may expect greater improvement, both in their 
incontinence and their health-related quality of life (HRQoL) following a TVT. 
Other factors that may have influenced the outcome of a TVT was not explored. For 
example, data on any previous surgery for POP or continence was not provided.  
This study illustrates how ePAQ data can be used when discussing treatment 
response. 
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Lower urinary tract and pelvic floor symptoms are also known to increase during 
pregnancy and pelvic floor symptoms can become worse 60.  
A prospective study aimed to evaluate the changes in pelvic floor symptoms and the 
effect of QoL during pregnancy 52.  Both an objective assessment of pelvic organ 
support (using the Pelvic Organ Prolapse Quantification [POP-Q] system) and 
subjective evaluation of symptoms with the ePAQ were performed in the second 
trimester and then repeated at 36 weeks gestation. There were no significant 
changes in POP-Q points or stage between the two visits except for a significant 
increase in genital hiatus (p = 0.0001) and perineal body length (p = 0.0001). The 
vaginal symptoms did not show any changes. Symptoms and bother with voiding 
difficulties and stress urinary incontinence increased during pregnancy. Constipation 
(p = 0.02) and evacuation subdomains improved significantly (p = 0.009). In the 
sexual domain, the only subdomain that worsened significantly (p = 0.03) was “sex 
and vaginal symptoms”. None of the pelvic floor symptoms impacted the QOL. 
There is a possibility that specific information was not disclosed as a paper copy of 
ePAQ was used as opposed to the electronic format.  
 
Treatment response 
The ePAQ is responsive to health status change following surgery and is suitable to 
be used as an outcome measure in urogynaecology. A study conducted by Jones et 
al (2009) 53 aimed to evaluate how responsive the ePAQ was in women who were 
undergoing TVT for stress urinary incontinence (SUI) or prolapse surgery.  
The results showed that at baseline the women who were undergoing a TVT scored 
high for the SUI domain and similarly, the women who were having prolapse surgery 
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also scored high in the prolapse domain. The scores reduced dramatically in these 
domains postoperatively. In the TVT group, the largest effect sizes were seen in the 
urinary domains for SUI, QoL and OAB. In the prolapse group, the largest effect 
sizes were seen in the vaginal domains for prolapse and quality of life.  
This indicates how useful used as comparison of their symptoms (pre and post-
operatively).  
 
Sexual function in a woman can become affected due to underlying pelvic floor 
disorders such as a pelvic organ prolapse (POP). There are different forms of surgery 
depending on the type of POP (posterior repair, anterior repair, anterior repair with a 
vaginal hysterectomy and a combined posterior and anterior repair). Women 
undergoing prolapse repair between 2008 and 2010 were asked to complete an 
ePAQ for the assessment of their symptoms.123 sexually active women had 
completed the questionnaire both pre and 3-6 month postoperatively. The results 
highlighted that vaginal surgery can improve pain with intercourse and sexual 
function related QoL in those undergoing an anterior repair or anterior repair and 
vaginal hysterectomy 54. Women undergoing a combined procedure had the least 
improvement in sexual function but the women who had a posterior repair (in 
isolation) had an improved sexual function, although pain during intercourse was still 
an issue. Overall, the completion of an ePAQ is helpful when discussing treatment 
response. 
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In another study by Dua et al (2012) 55 , 60 women undergoing posterior colporrhaphy 
had completed an ePAQ. A significant improvement was seen in bowel evacuation 
(42%), continence (37%) and bowel-related QoL (61%) scores. IBS score improved 
by 28%, but this did not reach significance. There was no significant change noted in 
constipation (0.5%). This study has illustrated the importance of assessing symptoms 
as a pre-operative ePAQ may prove valuable when discussing surgery and its 
potential impact on various symptoms with women. 
 
Many women undergoing sacral neuromodulation for faecal incontinence have 
coexisting pelvic floor dysfunction. Women with faecal incontinence underwent 
assessment using the ePAQ (Pre- and post-stimulator). It was found that ePAQ 
scores improved significantly more in the bowel continence domain than in other 
domains following Sacral Nerve Stimulation (SNS) treatment (P < 0.005). 
Improvement related to QoL in urinary symptoms and overall bowel function was also 
significant (P < 0.005). A global health improvement was reported in 58.1%, mainly in 
bowel evacuation (P < 0.01) and in vaginal pain and sensation (P < 0.05). This was a 
small study of 43 women with analysis of the data taking place over a 4.5-year 
period. The study has demonstrated global improvement in pelvic floor function in 
bowel, urinary, vaginal and sexual dimensions in women following SNS for faecal 
incontinence. 
 
Test-retest reliability 
Radley et al (2006) 57 conducted a qualitative study that considered how women 
perceived the completion of the ePAQ with the primary care setting. This data 
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suggested that after completing an ePAQ, women felt more prepared for their clinical 
consultation. Communication had improved and women felt the questionnaire was 
generally acceptable and easy to use  (P<0.001)56. In contrast, some women had 
reported it was too long and restrictive with its multiple choice format 61. 
 
Jones et al (2008) 58 performed a large study on women within the secondary care 
setting. This study looked at the data quality of completing ePAQ and found that the 
majority of the respondents had urinary symptoms (70.3%). There was a good 
response rate (596/599 completed ePAQ). As women were only recruited from 
secondary care, we do not have any data to compare (secondary vs. primary) from 
this cohort of patients. 
 
Overall these two studies proved that ePAQ was reliable and a good tool to detect 
change for women with pelvic floor disorders. 
 
Qualitative / miscellaneous data 
Omotosho and Rogers (2009) identify that patients may be reluctant to ask about 
sexual concerns while seeking health care. One study found that women who had 
completed ePAQ had answered most questions in three out of the four dimensions; 
the sexual dimension of the questionnaire had the highest ‘declined to answer’ 
(130/480 respondents) 59. This may indicate that the higher rates of completed data 
were due to the option of omitting specific sections i.e. the sexual dimensions. 
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Women of all ages may present with pelvic floor symptoms, how they are affected will 
be influenced by underlying factors. The ‘bother’ or impact of pelvic floor symptoms 
may vary between different age groups61. This is a useful consideration when 
counselling patients regarding the risk benefit ratio of various treatment options as 
this can change depending on the age and ‘impact’ of the condition.  
 
Quality of the studies 
The quality of the included studies was variable. The number of patients varied and 
most of the studies did not comment about the demographics of the non-responders. 
The quality assessment for the included studies is detailed in Table 4.  
  
 
4
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Table 4: Quality of studies included in the electronic Personal Assessment Questionnaire systematic review 
(One star for fulfilling each quality item within the selection and outcome categories and a maximum of two stars can 
be given for comparability, N/A not applicable) 
Author,  
date 
Representativeness 
of the sample 
Sample 
size 
Non 
respondents 
Ascertainment 
of risk factor 
Comparable 
groups 
Outcome 
assessment 
Statistical 
test 
Dua et al 
(2013)59 
** * X * ** ** *  
Dua et al 
(2013)59 
* * * * X * * 
Jones et al 
(2009)53 
* * X ** * * * 
Jha et al 
(2009)51 
** ** X ** * * * 
Dua et al 
(2011)54 
* **  X ** * * * 
Dua et al * * * ** * * * 
  
 
4
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(2012)50  
Jadav et al 
(2013)55 
* * * ** *  * * 
 Jha et al 
(2012)58 
* * * * X  *  
Elenskaia et al 
(2012)52 
*  ** X * X * * 
Radley et al 
(2006)56 
* * *. ** * * * 
Jones et al 
200858 
* ** * N/A X * * 
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Representativeness of the sample/ sample size 
There were limitations of using the Newcastle Ottawa scale when assessing the 
representation of the cohort in respect to the community. It was difficult to ascertain 
whether the results of a particular study would be more at risk of bias if the study was 
performed on a smaller cohort of patients. There may be an increased risk of bias if 
the cohorts of patients. Follow up of patients may vary from centre to centre or 
dependent upon the patients’ health. Therefore it may be difficult to compare similar 
groups of patients if their follow up appointment time and duration differed. Targeted 
patients may appear to be biased when performing a study and therefore the 
generalisability of results can be compromised. 
Non-respondents were recorded and reasons listed for some of the studies. 
 
Non respondents/ascertainment of risk factor 
Although the studies had demonstrated a selected population group, 5 out of the 11 
studies had no statement regarding non-respondents. This somewhat limited that 
particular part of the study assessment. In contrast, all studies had ascertained any 
risk factors by using secure patient data and a validated tool. 
 
Comparable groups/ outcome assessment 
In one study, there was no description of the sampling strategy (Jadhav et al, 2013).  
Jha et al ( 2012) 58 demonstrated that a large proportion of women did not complete 
the sexual dimension of their ePAQ but comparability between respondents and non-
respondent’s characteristics was satisfactory.  
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The results from the ePAQ completed pre and post intervention were used as an 
outcome measure of success. 
   
Discussion 
The use of ePAQ in pre and post-operative assessment 46,48,50,, treatment of LUTS 
and its utility in evaluation of pelvic floor related QoL has been established. The initial 
validation that was carried out in primary and secondary care had established the 
basic psychometric properties of the ePAQ 40 . This systematic review 67 highlighted 
the lack of evidence regarding the predictive ability of ePAQ for urodynamic 
diagnoses in women with LUTS. 
 A further study conducted within secondary care with a total of 599 women with 
pelvic floor disorders had looked into further tests of data quality. This study took into 
account the secondary factor analysis, internal consistency, descriptive statistics as 
well as the levels of missing data 51, 54.  Internal consistency and reproducibility have 
been identified as two important aspects of reliability 62.  
Results from the first study had established that the ePAQ was suitable for 
measuring symptoms,’ bother’ and quality of life in women who have pelvic floor 
disorders 40. 
Women who have recurrent pelvic floor disorders or present with a complex history 
(i.e. have underlying symptoms in all the ePAQ domains) require a valid measure of 
their health and impact on QoL. In this instance, the ePAQ can provide value and an 
insight into the ‘bother’ of each symptom, (to what extent it is an irritation or a 
nuisance). These data are potentially important to collect for clinicians who will be 
 47 
 
required to produce patient related outcome measures data to justify continuing 
support for their services. 
 
The ePAQ offers potential to improve efficiency and effective triage in health care 63; 
(Quality, Innovation, Productivity and Prevention, 2013). A significant advantage of 
this electronic method is improved response rates43, in addition to its eco-friendly 
(paper-saving) nature. The ePAQ was also associated with high satisfaction levels 
and lower levels of embarrassment than discussion with a health professional64. 
If consent is obtained from participants to use their data for research purposes, there 
is a potential to create a huge data resource.  
If women are using the urogynaecology service for the first time, they may be more 
likely to accept the ePAQ as the norm for data collection in this service. The relative 
anonymity created by the use of the ePAQ may enable sensitive and potentially 
embarrassing questions to be answered with greater ease.  
 
The fact that ePAQ can be completed remotely in patient’s own home, with the 
results being made available to clinicians for review, may enable further reduction in 
new-to follow up ratios of outpatient visits by only inviting women with on-going 
problems for further clinic review, as well as triaging patients to nurse-led or 
consultant-led clinics. Patients whose ePAQ responses suggest symptoms are much 
improved (confirmed by telephone) would not need to attend an outpatient clinic. 
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Limitations of ePAQ 
The ePAQ has its limitations as one could argue that the number of questions asked 
on the ePAQ is time consuming. The length of the questionnaire is important, it has 
been reported that a long questionnaire may prove burdensome to patients 
(Omatosho and Rogers, 2009).However, the initial evaluation of the ePAQ identified 
an average completion time of 20 minutes.  
Although the omission of a particular domain will not provide the clinician with some 
information, the ePAQ can still be used as a focus point in the assessment of the 
other domains. This allows for any issues to be explored in greater detail and also 
allows a reduction in the time spent answering irrelevant questions. For example, 
women who present to the clinic with urinary symptoms may choose to omit the 
bowel domain of ePAQ. The clinician may still question the patient’s bowel habits as 
this may be relevant to the treatment offered.  
In some NHS trusts ePAQ is not yet used extensively for various reasons including 
the cost implications as there is a reasonable cost involved in purchasing an ePAQ 
license. Additionally, in order to ensure good value for money a number of 
considerations must be taken into account: Investment from the hospital in hardware 
(PCs/Tablets), availability of network points or wireless networks and time available 
for staff to guide patients who struggle to complete the questionnaire. There is also 
the option to produce an ePAQ voucher for patients to enable them to complete the 
questionnaire at home.  
There are no alternatives for women who do not have access to a computer or are 
illiterate. Family members or friends may read the questions out for those who are 
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illiterate, but this presents the possibility that questions will not be answered openly 
due to the nature and sensitivity of issues.  
The ePAQ is available only in English, so some women who do not understand 
English or lack computer skills may not be able to complete it. Reluctance to change 
is another area where the use of the ePAQ may be limited and pose a potential 
difficulty, for example, some individuals may prefer to use paper questionnaires.  
Demographic details such as ethnicity, parity and body mass index are not included 
in the questionnaire, which may be seen as a limitation. The majority of the studies in 
this review included Caucasian populations. There is a lack of research regarding 
ethnic minority populations and the consequences of urinary incontinence 
(psychological, physical and social). Evidence from previous literature has already 
illustrated the importance of ascertaining the needs for incontinence care among 
ethnic minority groups65. Therefore, collecting some details like ethnicity, parity, 
beliefs could generate further evidence in these subgroups and help improve the 
management of UI amongst ethnic minority groups.  
We acknowledge that this systematic review may have weaknesses and we were 
unable to synthesise data as the primary studies were different. There was also a 
paucity of data and therefore we were somewhat limited with how we could draw 
conclusions from any common themes. The majority of the studies (9/11) also came 
from one recruiting centre which can potentially affect generalisability.   
Since the systematic review, we have conducted another study using  the ePAQ to 
illustrate improvement in OAB and bowel scores in patients who have anticholinergic 
or Mirabegron therapy 66. We found that there was a statistically significant 
improvement in the symptom score for OAB (p value <0.0005) and all of the bowel 
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domains (p value <0.0005) in women who had anticholinergic therapy. We concluded 
that ePAQ score on anticholinergic therapy appears to suggest that there is 
improvement in symptoms of OAB as well the bowels. Further research with a large 
cohort and complete data collection would provide more robust results. 
 
Conclusion 
In conclusion, the evidence gathered from the studies demonstrates that ePAQ is a 
useful tool in the assessment of QoL in relation to pelvic floor symptoms. It also 
enhances the facilitation of communication for both patient and clinicians and 
although reported to be a burden to complete the questionnaire, most women found it 
acceptable. In future studies, ethnicity and response rate could be studied in order to 
take into account any changing ethnicity trends amongst the British population. It is 
plausible that different religious and ethnic groups might have different views on the 
questionnaires that might affect completion rates. Previous studies have already 
highlighted the lack of information on such groups, hence further multicentre studies 
on ethnicity and acceptability will enable to increase the generalisability of the 
findings. Further research is required to assess the added value of ePAQ (along with 
bladder diaries, urine dipstick) in evaluation of OAB and the cost-effectiveness of this 
questionnaire for all the clinical utilities described in this chapter.  
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CHAPTER 3: URODYNAMICS & QUALITY 
ASSURANCE 
 
Background 
The precision and accuracy of the UDS procedure is vital in order to achieve the 
correct diagnosis, giving informed consent and also planning of the patient treatment 
pathway. 
Quality control (QC) is defined as an aggregate of activities (such as design analysis 
and inspection for defects) designed to ensure adequate quality 67. QC is deemed a 
crucial element of the Good Urodynamic Practice (GUP) guidelines, which were 
developed following poor QC observed during review of UDS traces from multi-centre 
trials by the International Continence Society (ICS) in 2002 28.  
The three main elements comprising of good urodynamic practice28 have been 
identified as:  
 A clear indication for and appropriate selection of, relevant test measurements 
and procedures,  
 Precise measurements with data quality control  
 Complete documentation and an accurate analysis and critical reporting of 
results. 
  Sullivan et al (2012) 60 state that the pressure or flow problems that easily occur 
during the UDS test can be sought and corrected. Invasive treatments i.e. surgery is 
influenced based upon UDS findings, therefore, it is paramount that QC is not 
compromised and accuracy is maintained throughout the test.  
 52 
 
It is of utmost importance that clinicians performing the UDS test are familiar with the 
equipment that is used during the procedure 68. UDS is a skilled procedure, which 
requires training in setting up the UDS equipment, calibration of the machine, 
interpreting the pressure/flow recordings and counselling patients. One of the 
difficulties often encountered during UDS is the ability to identify artefacts and 
interpret the results 69. 
 
A key aspect of maintaining the accuracy of UDS is to ensure that the initial resting 
pressures are correct and also recognised 70. Previous studies have shown that 
reliability parameters can be poor despite standardised test-retest situations 71. UDS 
can be further compromised by inconsistencies in clinical practices. Variations in the 
UDS procedure may vary from site to site and may be dependent upon the 
equipment and experience/training of the staff 72. Consistency and quality control is 
therefore paramount in UDS testing, particularly as the diagnoses/results may inform 
management decisions including invasive treatments such as surgery 28. 
 
As a previous research nurse working on the Bladder Ultrasound Study (BUS), a 
diagnostic accuracy study of transvaginal bladder wall ultrasound in Detrusor 
Overactivity, my role involved conducting the UDS test and discussing options in 
relation to the management of women who had OAB symptoms73. 
Standard Operating Procedures (SOP) are written instructions that document how to 
perform a specific activity. These are written to help ensure that the quality and 
consistency of the activity is maintained. In our trust we use the departmental SOP; 
the BUS study SOP for performing UDS was based on the same. This was provided 
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so that all of the trained clinicians within the urogynaecology department should have 
been able to perform this test in a consistent and standardised manner.  
 
Amongst NHS trusts that perform UDS, variations will exist regarding the equipment, 
catheters and filling rate of the test. This also applies to large multi-centre trials 
where it is possible that variations will exist due to differences in equipment and the 
training of staff 74. Nager et al (2007) 72 found that a significant number of staff had 
inadequate training in UDS and little clinical involvement in the care of patients 
undergoing this procedure. A survey carried out by Siriam et al (2002) 75 revealed 
that clinicians were reluctant to standardise UDS practice. However, it has been 
identified that clinical trials using outcomes of UDS studies require additional 
standardised procedures to ensure that inter-site variability is limited 63. We wanted 
to explore whether clinicians involved in recruitment to the BUS study were 
adequately performing this test using the recommended study SOP (Appendix 4). 
 
We aimed to audit the quality of UDS traces submitted to the Birmingham Clinical 
Trials Unit (BCTU) at the University of Birmingham (UoB), collected as part of the 
BUS study. 
We also wanted to assess whether or not recommended changes in UDS practice 
had been implemented following an initial audit among the recruiting centres for the 
BUS study.  
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Methods 
The BUS study protocol required all patients to have UDS and ultrasound scans of 
their bladder walls performed by two independent observers. The UDS studies were 
undertaken between May 2011 and May 2012 on women who had consented and 
were eligible to take part, and included 302 participants from 12 different centres 
across the UK. 
UDS traces were submitted to the BCTU at the UoB as part of the BUS study 
protocol. An assessment of compliance with good urodynamic practice was 
performed by checking the adherence to the GUP guidelines. The reliability of initial 
diagnosis at the time of UDS being undertaken was assessed in accordance to the 
BUS study SOP manual. 
Confidentiality of these results was maintained by entering the data into a Microsoft 
Excel spreadsheet which was then stored on an encrypted memory stick.  
 
An assessment of compliance with the UDS SOP for the BUS study and with GUP 
guidelines was performed on 64 (20%) of the first 302 UDS traces. The UDS traces 
were supplied by each of the recruiting centres and randomly selected by the BUS 
study trial co-ordinator. This was deemed to be adequate by the BUS study data 
monitoring committee. A consultant in urogynaecology and a urogynaecology 
research nurse from the lead centre (BWNFT), both of who perform UDS studies; 
assessed the traces independently. They were blinded to the centre and the 
urodynamicist and recorded the following: Position of filling cystometry, filling rate, 
the presence of a cough per minute to assess adequacy of subtraction, presence of 
cough both pre and post void, the concurrence with the diagnosis given and also 
 55 
 
whether there was adequate zeroing of the pressure transducers prior to 
commencing UDS.  
 
There are a number of potential diagnoses and these include detrusor overactivity, 
urodynamic stress incontinence, mixed urinary incontinence, voiding dysfunction, a 
stable bladder or low compliance.  
 
The results of this audit and reminders about following the SOP were shared with the 
collaborators via the newsletters and by emails to individual centres. We also 
discussed this at the BUS Study training days held 3 months and 15 months into the 
study. Following these interventions, a re-audit was performed on 60 urodynamic 
traces between June-December 2012 to assess the adherence. 
 
Results 
The initial audit found that all 64 traces had been performed using standard 
laboratory UDS studies. 
 
Compliance with good urodynamic practice 
Table 5 summarises the quality control criteria used to assess adherence to the 
recommended standard operating procedures (SOP) for BUS study which was based 
on GUP. 
 
Only 4 of the 64 traces had inadequate zeroing pressures before commencing the 
filling cystometry. The recommended position of sitting was documented in 52 traces, 
 56 
 
10 were in supine and standing position, and one was in supine position.                
For the remaining 1 woman, the filling pump had broken resulting in a gravity fill and 
the position of filling was not documented. 
 
Filling cystometry rate 
In 34 of the 64 traces, the recommended filling cystometry rate of 100ml per minute 
was followed; in three of the traces, the pump was slowed to 50ml per minute in the 
later part of the test. For 29 traces, cystometry filling was performed at a rate less 
than 10ml per minute. The pump was slowed down to try and obtain a clinical 
diagnosis if the woman had urgency without detrusor contractions or expressed a 
feeling of urge to void. The reasons for reducing the filling rate were documented in 
the UDS report. In one case, the woman’s bladder was filled at a rate of 30ml per 
minute because of the presence of detrusor contractions throughout the test. 
 
Cough pre and post void 
Patients should cough immediately before and after voiding to allow pressure 
transmission to be assessed. Compliance with the cough test pre void occurred in 
77% (n=49/64) of traces. Cough pre void was absent in 14% (n=9/64) of traces. In 
6% (n=4/64) of traces it was difficult to interpret whether the cough signal command 
had been initiated. In 3% (n=2/64) of traces, it was evident that the pressure catheter 
had fallen out before voiding, therefore the cough test would not provide accurate 
results. Compliance with the cough test post void occurred in 36% (n=23/64) of 
traces. Cough post void was absent in 25% (n=16/64) of traces. In 22% (n=14/64) of 
traces the rectal pressure catheter had fallen out, as indicated by a sharp decrease in 
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pressure, and in 175 (n=11/64) of traces it was difficult to identify whether both 
catheters (vesical and rectal) had fallen out. 
Each cough test had appropriate signals in the traces and any artefacts that were 
noted were rectified early on. 
 
Presence of one cough per minute 
The minimum recommendation for quality control for a cough signal, as defined by 
the ICS 28, is one cough per minute or every 50ml filled volume. Coughs per minute 
were evident in 78% (n=50/64) of traces, and absent in 22% (n=14/64). 
 
Reliability of initial diagnosis 
There was reviewer agreement with initial diagnoses at the time of the test in 91% 
(n=58/64) of traces. A total of 6% (n=4/64) of traces were considered to be of poor 
quality, resulting in a disagreement between the recruiting centre and the reviewers 
and 3% (n=2/64) of traces were given a different diagnosis following assessment by 
the reviewers’.  
The four traces of poor quality had originally been given a different diagnosis by the 
recruiting centre. However, the traces supplied were extremely difficult to interpret as 
the recording was of a poor quality. This resulted in a lack of interpretation and a 
diagnosis was unable to be reached. The recruiting centre was asked to send 
another copy of the UDS trace but the quality was the same as the previous one. In 
the two traces where the diagnosis had been changed, an initial diagnosis was 
disputed by the two auditors. There was evidence from the traces that calibration of 
the pressure transducers was not satisfactory at the start of the UDS procedure. 
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Artefacts had then been identified which had been mistakenly used to confirm a 
diagnosis. The discrepancies were then fed back to the recruiting centre and advice 
given regarding further investigations.  
 
Changes between the two audits 
A second audit of a further 60 UDS traces was conducted between June 2012-
December 2012 using the same criteria as the first audit following feedback to 
practitioners. Statistical comparisons between the two audits were performed using 
the Fisher Exact Test to generate P Values. Table 5 summarises the quality control 
criteria used to assess the adherence to good urodynamic practice. The comparison 
between the audit and re-audit compliance is also illustrated in this table.  
 
Table 5: Comparison between initial quality control criteria and adherence to 
Urodynamics-audit and re-audit of UDS traces 
Recommended actions in 
standard operating 
procedures 
Audit May 
2011-May 2012 
n= 64 (%) 
Re-audit June 2012-
December 2012 
n= 60 (%) 
P-
Values 
 
Adequate baseline pressures 60 (93.7) 57 (95) 1 
Filling in sitting position 52 (81.2) 38 (63.3) 0.029 
Recommended Cystometry 
filling rate100mL/minute 
34 (53.1) 43 (71.6) 0.042 
Cough pre-void 49 (76.5) 60 (100) <0.001 
Cough post-void 23 (35.9) 45 (75) <0.001 
Cough per minute 50 (78.1) 58 (96.6) 0.002 
Agreement between diagnoses 58 (90.6) 57 (95) 0.493 
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There was no significant comparison in the adequacy of baseline zeroing pressures, 
this was evident when checking the traces (p=1). However, any artefacts that had 
been identified at the start of the test and a reason for this had been documented.  
The GUP guidelines 27 state that the initial recorded subtraction pressures should be 
0-6cm/H20 in 80% of cases. It is possible that some clinical examiners do not ‘zero’ 
to the surrounding atmospheric pressure preceding the cystometry, but ‘zero’ to the 
intra-corporeal vesical and abdominal pressure at the start of the investigation.  This 
‘zero’ is therefore the pressure that is registered in each of the pressure lines before 
the start of the filling phase of the study.  
 
There was a significant reduction in the adherence of the recommended filling 
position (p= 0.029). There was a reported significant increase in the number of 
patients who had their filling cystometry at the recommended filling rate of 
100mls/min (p=0.042) and in the cough signals throughout the UDS procedure 
(p<0.001 and p=0.002). These significant improvements demonstrate a positive 
change in UDS practice as a direct result of reinforcing the importance of adhering to 
guidelines of clinical practice and procedures.  
 
The initial urodynamic diagnoses given by the recruiting centres had been re-
confirmed by the two assessors. However, there were no statistical comparisons to 
be made between the audit and re-audit (p=.493).   
An overall increase in compliance and adherence may have ultimately influenced the 
quality of the traces supplied.  
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Discussion 
The results of this audit show that urodynamic training and reiteration of guidelines 
and the SOP had a positive impact on most points related to performing UDS. 
Training and education provided through the use of emails, newsletters and study 
days significantly raised the compliance with most of the criteria assessed using the 
GUP guidelines except for the filling position.  
High quality recordings allow for a detailed interpretation to be made and a 
management plan to be implemented.  Artefacts on any UDS trace can cause a 
discrepancy if not rectified. This can have significant implications on the management 
of the patient following the UDS procedure. The strengths of this audit are that there 
was anonymisation of the centre and urodynamicist, clear standards and the audit 
loop was completed. A selection of UDS traces was readily available and the findings 
from both audits were shared amongst the recruiting centres.  
 
It is plausible that there are a number of factors that could have caused the filling 
position to decline following re-audit and this is potentially due to protocol violations 
related to performing UDS per their usual practice.  
 Hayek et al (2008) found that the patient’s position is a significant variable during 
UDS and concluded that between 33% and 100% of patients in the supine position 
would have a failed diagnosis of DO.  
There are potential limitations from this audit; we had only used a random selection 
of traces as opposed to auditing the entire BUS Study UDS traces. However, there is 
a possibility that if another QC audit on UDS traces had been conducted on other 
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National Health Service (NHS) trusts not involved in the BUS study, similar results 
may have been found.  
 
A re-audit could be improved by conducting phone interviews, teleconferences and 
questionnaires via an email where the UDS clinicians discussed their clinical practice 
and rationale.  
 
Recommendations for UDS in clinical practice 
In order to ensure that high quality standards are achieved and maintained, it is 
essential to do regular evaluation of UDS practice and audits within departments.  
Standardisation in UDS is paramount if results are to be reliable; implications can 
result in major discrepancies between the UDS diagnoses, the patient pathway 
following the procedure and future care surgical or conservative treatment options. 
There may be barriers to achieving this due to infrastructure, varying equipment, staff 
attitudes and the experience in performing UDS. Therefore, improvement in 
compliance with GUP guidelines could be incorporated by all centres using a 
standardised checklist for performance that the clinicians could use to complete and 
record the UDS results. 
Recommendations for use in UDS in research studies 
Assessments, multi-disciplinary team meetings and formal training can limit the 
variations between urodynamic centres. In large multi-centre trials, it is possible that 
there will be variations in the urodynamic procedures which include the equipment 
and training of staff and hence clinical trials using UDS as outcomes require 
additional standardised procedures 63. Indeed this is also true for any study when 
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evaluating the intervention or when using it as a primary outcome. Multi-centre 
urodynamic studies require a continuous QC process. Currently, urodynamic training 
in the United Kingdom is varied and ranges from a certificate course to individual 
study days. All centres need to share the same course content in order to achieve 
standardisation.   
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CHAPTER 4: PREDICTIVE VALUE OF THE ePAQ IN 
DETRUSOR OVERACTIVITY AND URODYNAMIC 
STRESS INCONTINENCE 
 
Background  
The systematic review detailed in Chapter 2 76 identified studies which demonstrated 
that the ePAQ was easy to use and generally acceptable 54. The completion of an 
ePAQ may potentially enhance the clinical consultation in regards to the types of 
questions asked by the clinician or the patient themselves. There is a need to find if 
there is any value added by ePAQ scores to the existing clinical assessment 
(examination, urine dipstick, cough stress test) in reducing the need for invasive tests 
like UDS. 
 Patients are experts in the experience of their symptoms and their impact on QoL.  
There is evidence in the literature that patients who have higher scores on disease 
specific QoL questionnaires have overall lower QoL77. In our systematic review 67 we 
did not find any studies on the diagnostic or predictive value of ePAQ in various 
urodynamic diagnoses. The priority is to establish benefit for patient health by trying 
to reduce the need for diagnostic evaluations where appropriate and by using a non-
invasive approach. There is a potential to reduce the cost of clinical 
activity/consultation time by using the ePAQ and focusing more on the specific areas 
of concern.  
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The objective of this study was to see if we could reduce the need for urodynamics 
by analysing whether the OAB or SUI scores of the urinary domain of the ePAQ –PF 
correlate well with UDS diagnoses. We hypothesised that women who have higher 
scores on ePAQ-PF for OAB or SUI will have a higher likelihood of DO or USI 
respectively. 
 
Methods 
This was a prospective cohort study that ran alongside the BUS study 64  where 
consecutive women who had been referred to the urodynamics clinic with a variety of 
LUTS were included if they fulfilled the following inclusion criteria: 
 Presence of overactive bladder +/- stress urinary incontinence symptoms 
 Age18 years or over  
 Comprehend and read English 
 Completed both the tests of UDS and ePAQ  
The exclusion criteria were: 
 UDS performed in the last 6 months 
 Did not speak, read or understand English 
 Urine dipstick positive to leucocytes or nitrites 
 Were on anticholinergics/antimuscarinics at the time of UDS 
 They did not consent to use of their ePAQ data 
 Previous Continence or POP surgery, within the last 6 months 
 
Although this study was performed alongside the Bus study, not all patients from one 
study belonged to the other (ePAQ) study.  
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Performance of index test 
The patients were encouraged to complete the ePAQ questionnaire as part of their 
routine clinical assessment in our centre. The details of this questionnaire are given 
in chapter 2. A designated ‘ePAQ’ room with three workstations and touch screen 
computers are dedicated for the completion of this questionnaire. ePAQ vouchers 
can also be generated in our clinics for our patients to complete at home. This is 
particularly useful if time constraints result in patients being unable to complete it 
whilst in clinic. Provided the woman had completed the urinary dimension, most 
importantly the OAB and SUI dimensions, the ePAQ results were printed off; the 
scores for OAB, SUI and voiding recorded onto the database. The scores from the 
OAB and SUI dimensions were then used to predict whether the patient will have DO 
or USI. For example, if a patient scored 60 for the OAB dimension and 40 for the SUI 
dimension we would predict that she would be diagnosed with DO, as OAB is the 
significant score. 
 
Performance of reference standard 
Reference standard is a test that confirms or refutes the presence or absence of a 
disease beyond reasonable doubt 49. UDS was the ‘gold’ or reference standard in this 
study. UDS was carried out by healthcare professionals (nurses or doctors) in 
accordance to the GUP guidelines 28. Women attended the clinic with a full bladder. 
Uroflowmetry was performed with the woman voiding in privacy on a flowmeter. 
Filling cystometry was performed with the woman in sitting position at 100mls/minute 
rate, followed by provocation measures and then voiding cystometry. All qualified 
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clinicians in our UDS clinic have attended a certified course in UDS and have at least 
3 years’ experience in conducting this procedure. 
 
The clinician who performed the UDS would record the findings and diagnosis on the 
UDS report and inside the patient’s notes. Where results were equivocal or 
inconclusive, ambulatory UDS was offered. The clinician performing this was blinded 
to the results of the ePAQ. Where ambulatory UDS was to be performed, it was 
intended that these results would be used as the final diagnosis on the database.  
Quality assurance checks were also performed on the index test of UDS 69. 
 
Design 
The study was designed to meet the requirements of the QUADAS-2 tool (Quality 
Assessment of Diagnostic Accuracy Studies) 78 (Appendix 5) and STARD (Standards 
for reporting of Diagnostic Accuracy) (Appendix 6). 
Selection bias was regarded as ‘low’/ reduced risk by recruiting all consecutive, 
eligible women into the study. Methodological bias was minimised by ensuring that 
the index tests and reference standard were performed independently (blinded to 
each other). Being blinded to the other results ensured that there was no previous 
knowledge on the diagnosis of the reference standard. Standard protocols for index 
and reference standard testing were drawn up and quality assurance checks were 
made on a sample of traces and a pre-specified statistical plan was followed. There 
is the potential risk of bias during the completion of ePAQ if the UDS was performed 
first (if distress was caused by undergoing the UDS procedure). The BUS study 
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found that acceptability of less invasive procedure (ultrasound) vs. UDS was more 
favourable 64. Thus in this study all participants complete the ePAQ prior to UDS. 
 
Ethics and Regulatory approvals 
The necessary approvals required to undertake any study were sought prior to the 
commencement of the study. The University of Birmingham (UoB) and the Research 
and Development (R&D) department at the BWNFT advised that formal ethical 
approval was not required (Appendix 7). This decision was made as both the 
reference standard and index test are used and the data collected as part of routine 
clinical practice within our department. In addition, there is an individual disclaimer at 
the end of the ePAQ seeking permission to use the data for research purposes and 
evaluation. This study was therefore considered a service evaluation project. 
 
Data collection 
Results of the index test and reference standard were collected on the same day, 
these (ePAQ scores and UDS diagnosis) were entered onto a Microsoft excel spread 
sheet (an encrypted trust safe stick was used for storage of this data). Patient 
identifiable details such as the woman’s name and address were omitted for patient 
confidentiality. An Access database was developed to enable data extraction from 
the excel spread sheet for the ease of statistical analysis. Any inconclusive results 
whereby the OAB or SUI scores on ePAQ were screened as “negative” or data was 
missing were excluded from analysis to avoid any misclassification. 
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Sample size and statistical analysis 
ePAQ may be useful if it has high sensitivity to detect conditions such as DO and 
hence negate the need for UDS. A proportion of the tests will return false positive 
results so the study was powered to have enough participants so that the lower limits 
of confidence intervals for both sensitivity and specificity exceed particular values. 
The BUS study 64 demonstrated that the prevalence of DO is around 60%. 
Thus a sample size of 400 will provide 240 sets of data to estimate the sensitivity and 
160 to estimate the specificity. This would allow estimation of sensitivities with 95% 
confidence intervals of width 10% for sensitivity values around 70-80% and 14% for 
specificity values around 70-80%. This level of precision will be adequate to assess 
the usefulness of the test. In addition, a sample size of 390 would provide 234 (60%) 
sets of data to estimate the sensitivity and 157 to estimate the specificity.  An 
observed sensitivity of 80% would have a 95% confidence interval with a width of 
10.65%. We thus aimed to recruit a sample size of 400.   
 
Possible factors that may influence ePAQ scores and QoL were assessed for their 
effect on ePAQ score and displayed as Box and Whisker plots include age, previous 
continence surgery, previous use of medication for bladder symptoms, menopausal 
status and parity 79, 80. For all patients the results of the ePAQ and UDS were 
summarised as 2x2 contingency tables with the OAB and SUI scores on ePAQ as a 
predictor of DO and USI, following the UDS diagnosis. These describe the 
relationship between the results of the index test and the reference standard at a 
given diagnostic threshold (point at which results are classified as positive or 
negative). The table includes the number of true positives (TP: those that have the 
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disease and test positive), false positives (FP: those that do not have the disease 
and test positive), false negatives (FN: those that do have the disease and test 
negative) and true negatives (TN: those that do not have the disease and test 
negative).   
 
Test performance was then summarised with 95% confidence intervals where 
appropriate as: 
1. Sensitivity [Sensitivity= proportion of true positives that are correctly classified as 
such-1=false negative rate], 
2. Specificity [Specificity= proportion of true negatives correctly identified as such-1= 
false positive rate]; 
3. Predictive values: Positive predictive value (PPV) and negative predictive values 
(NPV) [PPV and NPV]. PPV is related to the probability that the subject has a 
positive test result and truly have the disease. NPV is the probability that the 
subject has a negative test result under the gold standard.  
4. Likelihood ratios (LR) describe how many times more likely it is that a person with 
the target condition will receive a particular test result than a person without. 
Positive likelihood ratios greater than 10 or negative likelihood ratios less than 0.1 
are sometimes judged to provide convincing diagnostic evidence 81. 
5. The summary test performance (diagnostic odds ratio) was assessed by drawing 
receiver operating characteristic (ROC) curve which plot the sensitivity versus 1-
specificity at the different thresholds, and summarised as the area under the 
curve (AUC).  
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According to Zweig & Campbell (1993), ROC plots provide a pure index of accuracy, 
and are considered the gold standard in the statistical evaluation of a diagnostic test. 
The closer the curve is to the upper left hand corner the better the diagnostic 
performance 82. The AUC ranges from 0 to 1, with 0.5 indicating a poor test where 
the accuracy is equivalent to chance.  The AUC results were considered excellent for 
AUC values between 0.9-1, good for AUC values between 0.8-0.9, fair for AUC 
values between 0.7-0.8, poor for AUC values between 0.6-0.7 and failed for AUC 
values between 0.5-0.6 83, 84. Statistical analysis was performed using SPSS version 
22. Numbers and percentages were used for specific categories such as occurrence 
or episodes. Accuracy was expressed in relation to sensitivity and specificity and the 
data were described as mean and standard deviation for the numeric parametric 
variables collected as part of the results. A significant level was set as 0.05. Mann- 
Whitney and Fisher Exact tests were used to calculate the P-Values generated for 
the analyses of the ePAQ study. 
 
Results 
Participants 
During the 18-month study period of May 2013-November 2014, there were 451 
women who were eligible to take part. Exclusion of data with inconclusive index test 
results (n=61), gave a sample of 390 women who had a complete index test (ePAQ) 
and reference standard result (UDS).  Figure 4 demonstrates the participant flow. 
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Figure 4: Participant study flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics of the population 
The study population consisted of a variety of women who presented with LUTS, 
deriving from different ethnic backgrounds and age groups (Table 6). 
The mean age of these women was 53.4 years, with a standard deviation (SD) of 
14.6 and ranging between 21-92 years. The majority (n=294; 75%) of the women 
were White Caucasian and had two children (n=157; 40.3%). There were 30 (7.6%) 
women in the study population who were nulliparous and 330 (92.4) women were 
multiparous (Table 6).  
Assessed for eligibility (n=451) 
Excluded (n= 61) 
  Reasons: not meeting inclusion 
criteria, ePAQ not completed, OAB 
or SUI scores were screen negative 
Completed ePAQ Urodynamics performed 
                    Analysed (n= 390) 
Analysis 
Methods 
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Table 6: Characteristics of included participants (n=390) 
Age (Years) Mean (SD) 
Missing 
53.4 (14.6) 
0 (-) 
Ethnicity White 
Asian 
African or Afro-Caribbean 
Mixed/other 
Unknown/Missing 
294 (75.38%) 
67 (17.17%) 
17 (4.35%) 
7 (1.79%) 
5 (1.28%) 
Parity 0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
11 
30 (7.7%) 
43 (11.0%) 
157 (40.3%) 
85 (21.8%) 
33 (8.5%) 
21 (5.4%) 
9 (2.3%) 
4 (1.0%) 
4 (1.4%) 
3 (0.8%) 
1 (0.3%) 
Post-menopausal 
(LMP>1year) 
Yes 
No 
220 (56.4%) 
170 (43.5%) 
Previous treatment with anti-
muscarinics 
Yes 
No 
Cannot remember 
198 (50.7%) 
184 (47.17%) 
8 (2.05%) 
Previous incontinence or 
prolapse surgery 
Yes  
No 
11 (2.82%) 
379 (97.18%) 
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Women included in this study presented with symptoms of OAB, mixed urinary 
incontinence (MUI), stress urinary incontinence (SUI) and one reported a lack of 
bladder sensation post childbirth delivery (Table 7). 
 
Table 7: Relationship of presenting symptoms (Indications for Urodynamics) 
 
 
Presenting problems Frequency/number (%) Preceded by 
(UUI/SUI)/number (%) 
Mixed urinary incontinence 228 (58.4%) UUI= 193 (49.4%) 
SUI= 35 (8.9%) 
Overactive bladder 
unresponsive to 
conservative management 
161 (41.2%) N/A 
Pure stress urinary 
incontinence 
0 (0%) N/A 
Lack of bladder sensation 
(post-delivery) 
1 (0.25%) N/A 
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Urodynamic findings 
Of the 390 women, 262 (67.2%) of them were diagnosed with DO, of these 6 women 
had ambulatory UDS and had a final diagnosis of DO.   
USI was confirmed in 21.5% of the women (n=84/390). Various other diagnoses 
included stable/normal bladder, low compliance and MUI (Table 8). 
 
Table 8: Urodynamic diagnoses  
Diagnosis Frequency (n) Percent (%) 
DO 262 67.1 
USI  84 21.6* 
MUI (DO & USI) 32 8.21 
Normal/stable bladder 4 1.03 
Voiding dysfunction 4 1.03 
Low compliance 4 1.03 
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The various symptoms varied (Table 9) and in the group who presented with MUI, we 
categorised it by their predominant symptom (Stress or Urge). 
 
75/390 women had stress predominant MUI, of these 45 were diagnosed with USI 
and 23 had DO.  7/390 had MUI. 
 
147/390 women complained of urge predominant MUI, of these 106 were diagnosed 
with DO and 27 had USI.  11/390 had m MUI. 
 
166/390 women presented with OAB symptoms, 132 were diagnosed with DO, 11 
had USI and 14 had a diagnosis of MUI.  
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Table 9: Presenting symptoms against final urodynamic diagnosis 
Presenting Symptom (n) Urodynamics Diagnosis Number  
SUI  (n=0) - 0  
MUI- Stress predominant 
 
Detrusor Overactivity  23   
Urodynamic Stress Incontinence 45  
Normal/Stable bladder 0  
Mixed Urinary Incontinence 7  
Low Compliance 0  
Voiding Dysfunction  0  
MUI- Urge predominant Detrusor Overactivity  106  
Urodynamic Stress Incontinence 27  
Normal/Stable bladder 1  
Mixed Urinary Incontinence 11 
Low Compliance 1 
Voiding Dysfunction 1  
MUI- Equally bothersome (n=1) Urodynamic Stress Incontinence 1  
Overactive Bladder Detrusor Overactivity  132  
Urodynamic Stress Incontinence 11  
Normal/Stable bladder 3  
Mixed Urinary Incontinence 14 
Low Compliance 3 
Voiding Dysfunction 3  
Lack of sensation (n=1) Detrusor Overactivity 1  
 Total (n)=390 
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Analysis of OAB scores on ePAQ according to patient characteristics 
The Mann Whitney test was used to generate p-values for the analysis of the ePAQ 
scores.  
 
The OAB score was found to be significantly higher in those over the age of 65 years 
(p=0.009) (Figure 5). The median OAB scores for those under the age of 65 were 33 
and 42 in those who were over 65.  
 
In those with a parity greater than 2, the OAB score was significantly higher 
(p<0.001). The median values in those with less than two children were 33 and 42 in 
those who have more than two children (Figure 6). 
 
There was a significantly higher OAB score in those who had previously used 
anticholinergics (p<0.001) (Figure 7). 
 
The OAB scores were not significantly different in menopausal women (p=0.16) 
(Figure 8) or those who had previous continence surgery (p=0.083) (Figure 9). 
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We arbitrarily dichotomised to this age group (age 65) as we wanted to see if there 
was any difference in women once they retire (in regards to lifestyle choices). We 
wanted to see whether the ePAQ scores would differ in a woman over 65, who may 
(or may not) lead a less active life (Figure 5). 
 
Figure 5: Box and Whisker plot comparing overactive bladder score and 
women aged <65 and >65 years 
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Figure 6:  Box and whisker plot comparing overactive bladder score with 
women who had two or more children 
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Of the 390 women in the study, 198 women had tried at least one medication for 
OAB in the past, 184 hadn’t previously taken any and 8 of the women could not 
remember whether they had taken any at all. The median values in those who had 
tried medication were 50 and in those who had not tried any medication for their 
bladder symptoms, it was 30 (Figure 7). 
 
Figure 7: Box and whisker plot comparing overactive bladder scores in women 
who had previously tried/not used anticholinergics 
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Menopausal state 
Menopause was defined as the last menstrual period occurring 1 or more years ago. 
There were 389 women with known menopausal state of which n=217 were 
menopausal (55.8%).  
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There was a non-significant difference in the reported OAB scores in menopausal 
women (p=0.16) (Figure 8). The median values in those who were menopausal were 
40 and 33 in those who were pre-menopausal.  
 
Figure 8: Box and whisker plot comparing overactive bladder score OAB score 
and menopausal state 
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Continence surgery 
Of the 390 women, 379 (97.18%) had never had surgery, whilst 11 (2.82%) had 
reported previous continence surgery. There was a significant difference in those 
who had previously undergone continence surgery as opposed to those who hadn’t. 
The median values in those who had never had any continence surgery was 42.0 
and 50.0 in those who had previous continence surgery (p =0.083) (Figure 9). 
Sensitivity analysis on both the OAB and SUI score were not significantly different in 
those who had continence surgery. 
 
Figure 9: Box and whisker plot comparing overactive bladder score and 
previous continence surgery/no surgery 
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There was a median OAB score of 50 in those who had a clinical observation of DO 
during the UDS investigation. The median score for those who were not diagnosed 
with DO was 20 (Figure 10). 
 
Figure 10: Box and whisker plot comparing the electronic Personal 
Assessment Questionnaire overactive bladder score with the urodynamic 
observation of detrusor overactivity 
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Overactive bladder scores on ePAQ as a predictor of detrusor overactivity  
To assess the predictive ability of the OAB score from ePAQ for urodynamic 
diagnosis varying cut-offs for the OAB score were assessed (Table 10).  
 
 A cut off point of 25 or above had a sensitivity of 85.1%, specificity of 38.3% and a 
correctly classified diagnosis in 69.7% of cases. The positive likelihood ratio (LR) was 
1.3879.  
 
Women, who scored 50 for OAB, had a sensitivity of 51.1 %, a specificity of 79.7% 
and were correctly diagnosed in 60.5 % of the cases. The positive LR in this score 
was 2.518. 
 
Women, who were greatly affected by OAB and had scored 75 or above, had a 
sensitivity of 16.4%, a specificity of 95.3% and were correctly diagnosed in 42.3% of 
the cases. The positive LR in this group was 3.501. 
 
Thus as the OAB score on ePAQ increased so did the likelihood of DO on UDS up to 
a score of 75. Scores higher than this did not increase the likelihood of the diagnosis.  
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Table 10: Accuracy of the overactive bladder score on electronic Personal 
Assessment Questionnaire in predicting detrusor overactivity 
 
Cutpoint 
of ePAQ 
score 
for OAB 
domain 
Sensitivity Specificity Correctly 
classified 
LR+ LR- PPV NPV 
0 100.00% 0.0% 67.2% 1.0000 - 67.2 0.0 
≥ 8 99.2% 7.8% 69.2% 1.076 0.098 68.8 3.8 
≥ 14 94.3% 16.4% 68.7% 1.128 0.349 69.8 7.8 
≥ 17 94.3% 17.2% 69.0% 1.138 0.333 70.0 8.2 
≥ 25 85.1% 38.3% 69.7% 1.379 0.389 73.8 17.1 
≥ 33 74.4% 53.1% 67.4% 1.588 0.481 76.5 22.9 
≥ 42 63.4% 70.3% 65.6% 2.134 0.521 81.4 29.0 
≥ 50 51.1% 79.7% 60.5% 2.518 0.613 83.8 32.5 
≥ 58 38.5% 86.7% 54.4% 2.903 0.709 85.6 35.2 
≥ 60 22.5% 91.4% 45.1% 2.620 0.848 84.3 36.7 
≥ 67 22.1% 91.4% 44.9% 2.576 0.852 84.1 37.5 
≥ 75 16.4% 95.3% 42.3% 3.501 0.877 87.8 39.5 
≥ 80 8.8% 96.9% 37.7% 2.809 0.942 85.2 40.5 
≥ 83 8.4% 96.9% 37.4% 2.687 0.946 84.6 40.9 
≥ 92 6.9% 97.7% 36.7% 2.931 0.54 85.7 42.4 
100 2.7% 97.7% 33.8% 1.140 0.997 70.0 43.6 
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The AUC for DO (including Ambulatory UDS) was 0.709 (95% confidence interval; 
0.655-0.764) (Figure 11). 
 
Figure 11: Receiver Operating Characteristic curve of overactive bladder 
electronic Personal Assessment Questionnaire score and detrusor overactivity 
on urodynamics   
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Stress urinary incontinence scores on electronic Personal Assessment Questionnaire 
according to patient characteristics 
There was no statistical difference between the two age groups who had symptoms 
of SUI (p=0.16). The SUI scores on ePAQ had median values of 33.0 in the two 
stratified age groups (Figure 12). 
 
Figure 12: Box and whisker plot comparing stress urinary incontinence score 
with age <65 and >65 
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The SUI score was significantly higher in those with a parity greater than 2 (p<0.001). 
The median values for those who had less than two children were 33 and 44 in those 
who had two or more children (Figure 13).  
 
Figure 13: Box and whisker plot comparing stress urinary incontinence score 
in women who had two or more children 
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There was a small median difference between those who had tried anticholinergics 
(36.5) and those who hadn’t tried them before (33) but this was not statistically 
significant (Figure 14). Anticholinergics made no impact on the score for SUI. 
 
Figure 14: Box and whisker plot comparing stress urinary incontinence score 
in women who had previous/had not previously used anticholinergics 
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Both groups (surgery vs. non surgery) had a median score of 33.0 (Figure 15). 
 
Figure 15: Box and whisker plot comparing SUI score and previous continence 
surgery vs. no surgery 
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Menopausal status 
Of the 390 women, 170 (43.5%) were pre-menopausal and 220 (56.4%) were post-
menopausal. There was no significance between these two stratified groups when 
comparing their ePAQ scores for OAB and SUI (Chi 2 0.20 and the probability was 
chi2= 0.6566 with a 95% confidence interval). 
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Women who scored high for SUI on ePAQ were more likely to have a clinical 
diagnosis of USI (Figure 16). 
 
Figure 16: Box and Whisker plot comparing the electronic Personal 
Assessment Questionnaire stress urinary incontinence score with the 
urodynamic observation of urodynamic stress incontinence 
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Results for stress urinary incontinence scores on electronic Personal Assessment 
Questionnaire as a predictor of urodynamic stress incontinence  
 
The analysis of the SUI scores was conducted using the same methods for the OAB 
scores. The various ePAQ scores and the sensitivity and specificity are given in 
Table 11. 
.  
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Table 11: Accuracy of the stress urinary incontinence score on electronic 
Personal Assessment Questionnaire in predicting urodynamic stress 
incontinence 
Score for 
SUI on 
ePAQ 
Sensitivity Specif
icity 
Correctly 
classified 
LR+ LR- PPV NPV 
0 100.0% 0.0% 21.5% 1.000 - 21.5 0.0 
≥7 97.6% 15.4% 33.1% 1.153 0.155 24.0 37.9 
≥8 95.2% 19.6% 35.9% 1.185 0.243 24.5 44.1 
≥11 95.2% 19.9% 36.2% 1.190 0.239 24.6 45.5 
≥13 95.2% 20.6% 36.7% 1.199 0.231 24.8 47.0 
≥20 91.7% 27.8% 41.5% 1.269 0.300 25.8 57.0 
≥22 88.1% 38.2% 49.0% 1.426 0.311 28.1 65.4 
≥25 88.1% 38.6% 49.2% 1.434 0.309 28.2 66.7 
≥27 86.9% 38.6% 49.0% 1.415 0.340 28.0 67.4 
≥33 81.0% 49.0% 55.9% 1.588 0.389 30.4 74.6 
≥40 69.0% 61.8% 63.3% 1.806 0.501 33.1 81.1 
≥44 64.3% 69.9% 68.7% 2.138 0.511 37.0 84.3 
≥50 63.1% 69.9% 68.5% 2.099 0.528 36.6 85.3 
≥53 60.7% 77.1% 73.6% 2.654 0.509 42.1 88.4 
≥56 52.4% 84.3% 77.4% 3.339 0.565 47.8 90.2 
≥60 52.4% 84.6% 77.7% 3.410 0.563 48.4 91.5 
≥67 41.7% 87.3% 77.4% 3.269 0.669 47.3 94.0 
≥73 32.1% 90.5% 77.9% 3.392 0.750 48.2 96.2 
≥80 22.6% 93.5% 78.2% 3.461 0.828 48.7 98.6 
≥87 17.9% 95.4% 78.7% 3.903 0.861 51.7 101.2 
≥93 11.9 97.1% 78.7% 4.048 0.908 52.6 103.1 
≥100 6.0% 98.4% 78.5% 3.643 0.956 50.0 105.6 
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Women who had scored 8 or more for SUI had a sensitivity of 95.2%, specificity of 
19.6% and USI was then correctly classified in 35.9% of the cases. The positive LR 
was 1.185. With a score of 25 or more, the sensitivity was 88.1% and the specificity 
was 38.6% and USI was then correctly classified as such in 49.2% of the cases, with 
a positive LR of 1.434. An SUI ePAQ score of 40 or more has a sensitivity of 69.0%, 
specificity of 61.8% and USI was then correctly classified in 63.3% of the cases, and 
the positive LR was 1.806.  
Thus as the SUI score on ePAQ increased so did the likelihood of USI on UDS. 
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The AUC for USI was 0.731 (95% confidence interval 0.652-0.778) (Figure 17). 
 
Figure 17: Receiver operating characteristic curve of stress urinary 
incontinence electronic Personal Assessment Questionnaire scores and 
urodynamic stress incontinence on Urodynamics 
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Discussion 
Main findings 
This study concluded that based on the ROC curves, OAB and SUI scores have a 
positive relationship with the urodynamic diagnosis. Thus, the higher the ePAQ score 
the more likely the patient is to have a positive UDS diagnosis.  
Detrusor Overactivity (67.1%) was the predominant diagnosis observed during the 
UDS procedure. The detection rates of DO in women with OAB or urgency 
predominant MUI was 65.1%, indeed similar to other studies18.  Where deemed 
necessary, ambulatory UDS was also offered and performed, we found that an 
additional 1.7% (7/390 women) were diagnosed with having DO.  
 Women presented to the urogynaecology clinic with a variety of symptoms, with the 
58.4% of women complaining of MUI. There have been other reports in literature 
suggesting that MUI 85 or overactive bladder are the most prevalent type of UI in 
secondary care 86.  
In the ePAQ study we had 91 women from ethnic minority groups which increase the 
generalisability of the findings. Cameron et al 201387 identify that race and ethnicity 
have shown variable effects on UI in women. 
Factors identified in this analysis that may influence ePAQ scores for both OAB and 
SUI include age, previous continence surgery, previous use of medication for bladder 
symptoms, menopausal status and the parity.  
A number of characteristics were collected during the study period including previous 
pregnancies and the number of children each women had (where applicable), the 
woman’s menopausal status, previous use of medication for the bladder and also a 
history of surgical intervention for continence or pelvic organ prolapse.  
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Studies in the past have shown that pelvic floor symptoms have a different impact on 
women of different ages59. Unfortunately, we did not collect the overall QoL scores 
for impact of the symptoms in relation to the age groups. 
Minassian et al (2008)88 have identified risk factors for UI like increased parity, higher 
body mass, increased weight, hysterectomy and in addition; a history of surgery.  
 
Strengths and limitations 
Although there are many studies that have utilised ePAQ-PF for treatment response 
and success 67 to the best of our knowledge, this is the first study to assess the 
predictive ability of ePAQ-PF in the urodynamic diagnoses. The study was 
prospective and recruited consecutive women presenting with LUTS from ethnically 
diverse groups and achieved its target sample size. The prevalence of DO in our 
study was similar to that reported in literature 89, 90. In our study, ambulatory UDS was 
offered to the appropriate women whose symptoms of UUI were not reproduced 
during the laboratory UDS studies. Ambulatory UDS may have a higher pick up rate 
of DO 37. The false positive and false negative rates were analysed and the potential 
influence of patient characteristics assessed. Quality control checks were done on 
some of the urodynamic traces to ensure that the gold standard test was robustly 
performed. 
The robust design of this study increases confidence in the fact that the estimates of 
diagnostic accuracy are valid. All the criteria for a high-quality test accuracy 
evaluation have been met 78, 91. There is little data on ethnic minorities and UI 65, 
however almost 25% of our study population were of a black or minority ethnic group 
enhancing the generalisability of the results. 
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Limitations of the study are that we only looked at the scores relating to the OAB and 
SUI domains for the urinary component of the ePAQ. It is therefore plausible that the 
other domains such as pain, voiding and QoL may have provided further information 
and analysis to the overall diagnosis given. We did not audit all the urodynamic 
traces but the data monitoring committee for a bigger study 64 felt that random 
sampling was adequate. 
We could not assess the impact of inconclusive results as these were not formally 
assessed. Although there was data collected on various patient characteristics, it has 
been acknowledged that an assessment of these would need to be conducted to see 
whether they have any influence over the ePAQ scores. For example, logistic 
regression models would need to be performed to provide further clarification on 
whether specific characteristics may influence the overall predictive ability of ePAQ. 
This could include information such as the patient’s mode of delivery i.e. (normal 
vaginal, caesarean section, instrumental delivery), body mass index, and the impact 
of medical or surgical treatment. 
 
One area of concern in diagnostic accuracy research is misclassification made by the 
reference standard 92.  UDS is known to be an imperfect gold standard test as a 
proportion of women, who have OAB symptoms, do not have a clinical diagnosis of 
DO following UDS 69. UDS is also known to be less than 100% reproducible in 
previous studies of patients with overactive bladder and healthy volunteers 81. Errors 
in the reference standard typically lead to underestimation of sensitivity and 
specificity but misclassification rates would have to be extreme for no relationship to 
be observed at all 93. 
 101 
 
Having an imperfect gold standard (poor reproducibility of UDS) for the reference 
may have affected the test accuracy of our index test (the ePAQ). However, in the 
absence of another reliable diagnostic test for lower urinary tract dysfunction, 
clinicians have to utilise the UDS test which has been the accepted diagnostic test. 
The performance and interpretation of UDS in this ePAQ study was influenced by the 
results of our assessment of the quality assurance of UDS from the BUS study 
(Chapter 3) and thus performed under strict guidance with quality checking. 
 
Future research 
 I intend to analyse the ePAQ data retrospectively to find out what was the cut off for 
OAB or SUI scores beyond which women ended up with surgery. This might help us 
counsel women on the possibility of needing invasive treatment in those with higher 
scores or higher impact on QoL earlier to improve patient compliance, satisfaction 
and may be reduce healthcare related costs. 
 
Further research could assess the value added by ePAQ over and above the routine 
evaluation of OAB in clinical practice. Randomised controlled trials investigating 
treatments based on UDS vs. ePAQ OAB scores should be undertaken to determine 
the utility of UDS.  
 
Finally, if multivariable logistic regression identifies several prognostic variables for 
UDS diagnoses then these could be incorporated in a prediction model for both UDS 
diagnosis and/or treatment need. 
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CHAPTER 5: DISCUSSION 
 
Introduction 
Millions of women worldwide are affected by urinary incontinence; many factors 
associated with this often leads to suffering and eventually, the individual seeking 
medical advice. Conservative treatment is ideal but in those who experience failure of 
this, UDS is often recommended. The UDS test is not 100% reproducible and has 
associated risks e.g. infection. The NICE guidelines (CG171) for urinary incontinence 
in women (2013) suggests a number of questionnaires which can be used to assess 
evaluation of treatment therapies 94 (Appendix 1).  Electronic personal assessment 
questionnaire is a validated questionnaire which is used to assess the pelvic floor 
specific QoL (detailed in chapter 2) in our department. We wanted to study the 
evidence on diagnostic, prognostic and other utilities of ePAQ. We also wanted to 
assess whether this instrument could be used to reduce the need for invasive tests 
like urodynamics. 
 It is essential that the recognition and correction of abnormalities during the UDS 
procedure i.e. inadequate resting pressures are sought and remedial action taken. 
Quality control and regular audits of compliance to UDS procedures are required in 
order to ensure that high standards are performed. In addition, improvement can be 
sought and problems rectified if identified during an audit.  
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There were three specific objectives in this thesis which we have achieved:  
 
1. A systematic review of the literature available to assess the use of the ePAQ in 
clinical practice for women with lower urinary tract symptoms has been performed. 
2. Quality control of the urodynamic traces used in the study was performed.  
3. Assessed the ability of the electronic Personal Assessment Questionnaire (ePAQ) 
to predict a diagnosis of DO on UDS in women with OAB and predict a diagnosis of 
USI in women who have SUI. 
 
The main findings and conclusion for each of the above has been discussed in the 
preceding chapters (2-4). This final chapter reports on the key findings and limitations 
of the study. 
 
Main findings 
Evaluation of the index test (ePAQ) 
Of the 11 studies discussed in the systematic review (Chapter 2) by McCooty & 
Latthe 76, it is evident that the ePAQ has been established as a validated tool that 
can be used for women who have lower urinary tract and pelvic floor dysfunction. 
The data obtained by completing the questionnaire are considered useful in terms of 
measuring symptoms, their impact ‘bother’, and health-related QoL. Data collected 
pre and post treatment are particularly useful in detecting how patients perceive the 
acceptability of their condition, the success of the treatment and improvement or 
deterioration in their health. 
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Various study designs and methodological factors were used amongst the studies 
and all population groups easily identified as having pelvic floor disorders or 
intervention for continence. The completion of an ePAQ appears to be generally 
more acceptable among women who complete this during their consultation visit as 
opposed to completing at their second appointment (follow up visit). It is optional, and 
therefore the choice to omit sensitive or potentially challenging issues may be seen 
as an advantage to the patient. The systematic review also found that older women 
were less concerned by sexual symptoms. This may potentially enhance the clinical 
consultation in regards to the types of questions asked by the clinician or the patient 
themselves.  
Contrary to findings from previous studies demonstrating the usefulness of the ePAQ 
to assess women pre and post intervention, there were no studies found on the 
predictive ability of ePAQ and UDS diagnoses. Thus our focus and objective for the 
main study was to assess the ability of this tool in predicting the diagnosis of USI and 
DO in women who complaining of OAB and/or SUI. 
 
Evaluation of the standard reference test (UDS) - quality control audit 
The QC audit on UDS performed demonstrated a positive impact in most of the areas 
that were assessed. The audit and re-audit highlighted the importance of education 
and training in achieving compliance with GUP guidelines for UDS. 
 
Re-iterating information and results can increase the level of adherence and maintain 
confidence in the professionals performing a test. The increase in compliance with 
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guidelines and SOPs has a benefit to those interpreting results and in this audit, 
reduced the variables that had been seen previously.  
 
Ability of ePAQ to predict a diagnosis of detrusor overactivity and urodynamic 
stress incontinence  
Based on the ROC curves, the ePAQ has fair ability to predict the urodynamic 
diagnoses of DO (0.709) and USI (0.731).  
 
A less invasive way of assessing these women is desirable and it is hoped that one 
may find means of reducing the need for UDS. 
 
ePAQ is widely used in the urogynaecology department at the BWNFT for the 
assessment of such women. This is often instructed to be carried out prior to clinical 
consultation. Our study found a small number of women had declined for their data to 
be used for research purposes, in this instance this group of women were 
immediately excluded from the study and any further analysis.  
 
Strengths and limitations of this thesis 
The ePAQ systematic review did not illustrate any studies in relation to predictive 
ability and therefore, no comparable data was available. 
The studies reviewed were of variable quality. Common themes were identified and 
groups derived in accordance to the outcomes. There is a potential risk of bias as 
most studies were reported from one centre where ePAQ was developed.  
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The reference standard QC audit was performed as part of a multi-centre study, 
where 20% of the study population were randomly selected. It is therefore difficult to 
assess and identify how many of these traces were from our centre alone as the 
audit feedback was given to each centre. The UDS traces from our study would have 
been more compliant to the GUP guidelines and in accordance to our departmental 
SOP on UDS.  
 
The design of this ePAQ test accuracy study increases confidence in the fact that the 
estimates of diagnostic accuracy are valid. All the criteria for a high-quality test 
accuracy evaluation were considered and met using the QUADAS- 2 tool and 
reported using the STARD tool. 
 
A strong component of this ePAQ study is that a large number of patients (n=390) 
were included and the reasons for inconclusive data had been provided. This sample 
allowed for both analyses of the index and reference standard test. The women in the 
ePAQ study were from varying age groups, ethnicity and had various bladder 
symptoms. Doshani et al (2007) had previously found that little studies exist on the 
black and ethnic minority race 80; our study population found that almost 25% were 
from a black or minority ethnic group.  
 
Women were only included if they had accepted the disclaimer at the end of their 
completed ePAQ. There was the potential risk of bias during the completion of ePAQ 
if the UDS was performed first (if distress was caused by undergoing the UDS 
procedure).  
 107 
 
 
The main limitation in this ePAQ study is that the total score for OAB and SUI had 
been utilised to draw the conclusions of the accuracy in predicting the diagnosis of 
DO and USI. There are individual questions that make up the overall score for both 
the USI and OAB domain. These were not looked at which may explain why for the 
OAB score there was some decrease in predictive utility at scores above 75. 
 
Clinical implications 
The ePAQ provides an additional instrument to clinical history in enhancing the 
confidence in providing a clinical diagnosis and relevant treatments. It also helps 
patients to be clearer in their mind as to whether their mixed urinary incontinence 
symptoms are stress or urge predominant and this will help to prioritise the relevant 
treatments. The ePAQ by itself is only a fair test in predicting urodynamic diagnoses 
and hence cannot replace this test.  However, it can be used as an add on test to 
guide therapies based on patient ‘bother’ and also assess treatment response. 
 
Implications for future research 
As clinicians it is our duty to provide evidence-based health care for our patients. We 
need to find ways of improving the management and treatment of women with LUTS 
and or other bladder conditions such as detrusor overactivity. 
The discovery and evaluation of factors that might be useful as modifiable targets for 
interventions to improve outcomes is known as prognostic factor research (Riley et 
al, 2013) 84. A prognostic factor has been identified as any measure that, among 
people with a given health condition (start point), is associated with a subsequent 
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clinical outcome (endpoint). This particular type of research could be useful within the 
urogynaecology remit as many women are living with their bladder conditions for a 
longer period. In considering prognostic research we need to evaluate the broader 
healthcare impacts 95 (age, health conditions, treatment response) and build a 
prediction model. The first step in building any prediction model is to assess the 
factors that may have predictive ability- for example (BMI, parity, surgical history, age 
of patient, ethnicity etc.). These factors individually may not have the ability to be 
used as a stand-alone test; however they could be incorporated as factors within the 
model. 
 
In future, we need to assess the value added by OAB and SUI scores on ePAQ to 
the information already obtained from routinely used initial non-invasive tests (history, 
bladder diary).  
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